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ABSTRACT OF DISSERTATION

HEPATIC CYTOCHROME P450 REDUCTASE-NULL MICE AS AN ANIMAL
MODEL TO STUDY ELECTRON TRANSFER PATHWAYS IN CHOLESTEROL
SYNTHESIS AND CYP2E1-MEDIATED DRUG METABOLISM
NADPH-cytochrome P450 reductase (CPR) is a flavoprotein containing both
FAD and FMN and functions as the electron donor protein for several oxygenase
enzymes found on the endoplasmic reticulum of eukaryotic cells, including
cytochrome P450s involved in drug metabolism and cholesterol biosynthesis.
As many as three enzymes in the cholesterol biosynthetic pathway have
been demonstrated, or proposed, to use CPR as a redox partner: squalene
monooxygenase, which converts squalene to 2,3-oxidosqualene; lanosterol
demethylase, a cytochrome P450 (CYP51); and 7-dehydrocholesterol reductase,
the final step in cholesterol synthesis. In yeast CPR can be replaced by the
NADH-cytochrome b5 pathway, but this has not been demonstrated in animals or
plants.
My studies with hepatic cytochrome P450 reductase-null mice have
revealed a second microsomal reductase for squalene monooxygenase that was
not previously detected. Studies carried out with hepatocytes from CPR-null mice
demonstrate that this second reductase is active in whole cells and leads to the
accumulation of 24-dihydrolanosterol, indicating that lanosterol demethylation,
catalyzed by CYP51, is blocked. These results demonstrate that this second
reductase plays a significant role in supporting squalene monooxygenase but not
cytochrome P450-mediated reactions.
7-Dehydrocholesterol reductase (E.C. 1.3.1.21) catalyzes the reduction of
the 7-8 double bond of 7-dehydrocholesterol to yield cholesterol. It has been
suggested that cytochrome-P450 reductase is required for this reaction. My
studies show that 7-dehydrocholesterol reductase is enzymatically active in CPRnull microsomes, with activity equal to or greater than that found in preparations
from wild-type mice.
Mammalian cytochrome b5, which can accept electrons from either
cytochrome P450 reductase or NADH-cytochrome b5 reductase, is known to be
involved in augmenting some P450-dependent monooxygenase reactions.
Cytochrome P450 2E1 has been found to exhibit reasonable rates of turnover via
an NADH–cytochrome b5 pathway in reconstituted enzyme systems and in

heterologous hosts. Using microsomes from hepatic CPR-null mice, I have
determined that NADH-dependent CYP2E1 activity in the absence of NADPHdependent activity constituted approximately 10% of CYP2E1 activity observed in
microsomal preparations with NADPH from wild-type mice. However, little or no
CYP2E1 activity could be detected in primary hepatocytes isolated from CPR-null
mice.
KEYWORDS: Cytochome P450 reductase, Squalene monooxygenase,
Lanosterol 14alpha-demethylase, 7-Dehydrocholesterol reductase, CYP2E1
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HEPATIC CYTOCHROME P450 REDUCTASE-NULL MICE AS AN ANIMAL MODEL
TO STUDY ELECTRON TRANSFER PATHWAYS IN CHOLESTEROL SYNTHESIS
AND CYP2E1-MEDIATED DRUG METABOLISM

CHAPTER ONE: CYTOCHROME P450 REDUCTASE
Introduction
NADPH-cytochrome P450 reductase (CPR) is a flavoprotein containing both FAD
and FMN and functions as the electron donor protein for several oxygenase enzymes
found on the endoplasmic reticulum of eukaryotic cells. Figure 1.1 is a composite
illustration showing NADPH-cytochrome P450 reductase and its electron partners.
Among these oxygenases, the cytochromes P450s are a family of enzymes involved in
the metabolism of many drugs and xenobiotics and in the synthesis of steroid hormones
and other lipid signaling molecules; heme oxygenase catalyzes the first step in the
degradation of heme to bilirubin; and squalene monooxygenase has been identified as
the rate-limiting enzyme in the committed pathway for sterol biosynthesis. CPR has
also been suggested to donate electrons to 7-dehydrocholesterol reductase in the sterol
synthesis pathway, and to cytochrome b5, which supports both sterol synthesis and the
fatty acid desaturase and elongase pathways. Cytochrome b5 has been shown to
enhance some P450 reactions and several mechanisms for this effect have been
proposed.
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Figure 1.1: NADPH-Cytochrome P450 reductase and its electron partners.
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Expression and regulation
Mammalian NADPH-cytochrome P450 reductase (CPR) was first discovered by
Horecker in 1950 (Horecker 1950) as an NADPH-specific cytochrome c reductase.
Later studies showed that this flavoprotein is a membrane-bound protein anchored to
the endoplasmic reticulum by a NH2-terminal hydrophobic peptide (Black, French et al.
1979). Rat and human cytochrome P450 reductase cDNAs were cloned in the 1980’s.
Human cytochrome P-450 reductase is encoded by a single gene located on human
chromosome 7(pter-q22), while a single copy of mouse cytochrome P450 reductase
gene is located on chromosome 6 (Simmons, Lalley et al. 1985; Yamano, Aoyama et al.
1989).
Cytochrome P450 reductase is a house-keeping gene widely expressed in various
tissues with highest level in the liver, where the cytochrome P450 system is highly
expressed. The level of CPR expression is mainly regulated at the transcriptional level
by the pituitary-thyroid axis. Thyroid hormone is necessary to maintain CPR expression
in hepatocytes. In steroidogenic tissues, such as adrenal gland, a high level of CPR
expression appears to be regulated by adrenocorticotropic hormone (ACTH) (O'Leary,
Beck et al. 1994; O'Leary, Li et al. 1997).
Structure of cytochrome P450 reductase
Cytochrome P450 reductase belongs to a growing family of mammalian diflavin
reductases including nitric oxide synthase, methionine synthase reductase, and
cytosolic protein NR1 (Gutierrez, Munro et al. 2003). These diflavin reductases contain
one molecule each of FMN and FAD. It has been suggested that cytochrome P450
reductase had evolved by an ancestral gene fusion event which brings two flavins in
close proximity for efficient electron transfer. The NADPH/FAD domain has a strong
structural resemblance to ferredoxin-NADP reductase and the FMN domain appears
homologous with flavodoxins (Porter and Kasper 1986; Porter 1991). The threedimensional structure of the cytochrome P450 reductase was determined by X-ray
crystallography (Wang, Roberts et al. 1997). Cytochrome P450 reductase is composed
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of four structural domains including the FMN-binding domain, the FAD- and the NADPbinding domains, and a domain which acts as a flexible hinge region to orchestrate
interaction between the two flavin-containing domains for electron transfer, as shown in
figure 1.2. An NH2-terminal membrane-binding domain anchors the protein to the
cytosolic side of the endoplasmic reticulum. Two recent studies suggests that two FMNbinding domains exists on CPR molecule which allows the FMN to "swing" in and out in
relation to the rest of the CPR molecule and to shuttle electrons from FAD to CPR
partners (Lamb, Kim et al. 2006). The movement is consistent with previous
biochemical findings that describe the ease with which FMN dissociates from the
enzyme, which would coincide with FMN release and binding (Hall, Vander Kooi et al.
2001).
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Figure 1.2: Ribbons structure illustration of NADPH-cytochrome P450 reductase
with bound FAD, FMN and the adenine portion of NADPH. This figure was adapted
from Wang et al (Wang, Roberts , 1997)
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Electron Transfer and Interaction
Cytochrome P450 reductase is a diflavin protein containing both FAD and FMN in
equal proportions. Cytochrome P450 reductase binds NADPH and accepts a pair of
electrons through its FAD moiety. Electrons are then transferred to the FMN moiety and
then to P450 enzymes or other electron acceptors. Studies have shown that CPR
functions as an electron bridge coordinating electron supply from NADPH, an obligatory
two-electron donor, to one electron acceptors, by stabilizing the one-electron reduced
form of the flavin cofactors FAD and FMN (Vermilion, Ballou et al. 1981). Under
physiologic conditions the enzyme was proposed to cycle between the 1- and 3-electron
reduced states, as shown in Figure 1.3 (Vermilion and Coon 1978).
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Figure 1.3: Electron flow into NADPH-cytochrome P450 reductase from NADPH by
hydride transfer. The reductase cycles between a three- and a one-electron reduced
state. FAD accepts two electrons from NADPH, FMN acts as a one-electron
donor/acceptor and shuttles a single electron to the downstream partner.
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CPR primarily interacts with its downstream electron acceptor proteins through
electrostatic charge pairing. Multiple acidic carboxylate groups of CPR pair with basic
amino acids on the various electron acceptor proteins (Nisimoto 1986). Figure 1.4
illustrates, in cartoon format, the interaction of NADPH-cytochrome P450 reductase and
cytochrome P450s. It has been shown that cytochrome P450 forms a dipole across the
molecule, with the positive charge at the proximal face of the protein where the heme
makes its closest approach to the surface of CPR. There is evidence for an additional
hydrophobic component responsible for bringing the two proteins close enough together
for electron transfer (Nadler and Strobel 1988; Hasemann, Kurumbail et al. 1995). Other
electron acceptor proteins, such as cytochrome b5, heme oxygenase, and squalene
monooxygenase probably interact by the same mechanism (Ono, Ozasa et al. 1977;
Enoch and Strittmatter 1979). Site-directed mutagenesis studies have shown that CPR
mutations differentially affect the interaction with P450 and cytochrome c, suggesting
that these two proteins bind to CPR in different manners. Studies with cytochrome b5
indicate that its binding site on CPR is also distinct from that of P450 (Tamburini and
Schenkman 1986). These studies indicate that each redox partner has a slightly
different interaction with CPR.
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Figure 1.4: Diagram illustrating the interaction of NADPH-cytochrome P450
reductase and cytochrome P450s. Adapted from the version drawn by Porter
(http://www.uky.edu/Pharmacy/ps/porter/CPR_enzymology.htm).
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The catalytic turnover of cytochrome P450s in some cases can be synergistically
increased by cytochrome b5. Cytochrome b5 can be reduced by either NADH-dependent
cytochrome b5 reductase or NADPH-dependent cytochrome P450 reductase. The exact
mechanism by which cytochrome b5 affects P450-dependent reactions remains
controversial.
Liver-specific deletion of cytochrome P450 reductase
The cytochrome P450 reductase gene has been deleted in Saccharomyces
cerevisiae and CPR-null yeast are able to survive by using the cytochrome b5/ NADHdependent b5 reductase system to supply both electrons to its downstream partners
(Lamb, Kelly et al. 1999). However, complete loss of the P450 reductase gene results in
embryonic lethality at day 11 of gestation in mouse, further characterized by
developmental abnormalities in the neural tube, cardiac, eye and limb (Shen, O'Leary et
al. 2002). These results emphasize the important role P450 reductase plays in providing
electrons to enzymes important for development, including many involved in cholesterol
synthesis and breakdown, retinoic acid metabolism, and heme catabolism. Mice with a
conditional deletion of hepatic cytochrome P450 reductase have been generated from
two groups individually using Cre/loxP system (Gu, Weng et al. 2003; Henderson, Otto
et al. 2003; Wu, Gu et al. 2003; Weng, DiRusso et al. 2005). These two laboratories
independently developed a mouse model with liver-specific deletion of the Cpr gene by
cross-breeding the Cprlox mice with transgenic mice having liver-specific Cre expression
(Albumin-Cre). Hepatic CPR-null mice were able to survive and breed. Deletion of the
P450 reductase gene in the liver of adult mice by the Cre/lox system appears to lead to
an impaired ability to both generate cholesterol and to eliminate it through bile acid
synthesis, and is characterized by elevated hepatic lipids, reduced serum cholesterol
levels and reduced bile flow. Furthermore, hepatic reductase-null mice completely lost
microsomal P450 function in the liver, resulting in a five-fold induction of P450 enzymes
with essentially no activity. Phenobarbital administration in hepatic reductase-null mice
induced prolonged sleep at a dose that produced no sleep in wild-type animals. Dosing
of acetaminophen led to a 90% drop in hepatic glutathione levels and a rise in serum
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indicators of liver failure in wild-type animals, whereas glutathione levels and
biomarkers of liver health remained stable in P450 reductase-null animals (Gu, Cui et al.
2005).
The relationship between hepatic phenotype and changes in gene expression in
liver-specific cytochrome P450 reductase-null mice has been performed using gene
microarray analysis by two different groups (Wang, Chamberlain et al. 2005; Weng,
DiRusso et al. 2005). Overall, hepatic mRNA levels in control and CPR-null mice
exhibited a number of marked differences including genes involved in pathways of
lipid/sterol metabolism and cytochrome P450s. In the hepatic CPR-null mouse model,
induction of several cytochrome P450 genes was reported, including CYP1A2, CYP2A5,
CYP2B10, CYP3A11, and CYP3A13 mRNAs. CYP2E1 mRNA was expressed
abundantly in mouse liver, although the mRNA of CYP2E1 level was not affected by
hepatic CPR-deletion. The expression of certain P450 mRNAs was decreased in CPRnull livers. The expression level of Cyp7b1 (oxysterol 7α-hydroxylase), which is involved
in bile acid synthesis, decreased by 50%. The mRNA levels of most of the enzymes
involved in cholesterol biosynthesis were increased significantly in the CPR-null livers.
The expression level of 3-hydroxy-3-methylglutaryl-CoA reductase, which catalyzes the
rate-limiting step of cholesterol biosynthesis, increased by 1.56-fold. The transcription
levels of squalene monooxygenase, 7-dehydrocholesterol reductase and CYP51, which
have been assumed to require cytochrome P450 reductase for activity, have been
shown to be increased by 2-fold in one hepatic CPR-null model (Wang, Chamberlain et
al. 2005), but were not significantly affected in the CPR-null liver generated from
another lab. (Wang, Chamberlain et al. 2005; Weng, DiRusso et al. 2005)

Copyright © Li Li 2006
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PART ONE: ELUCIDATION OF AN ALTERNATIVE ELECTRON TRANSFER
PATHWAY IN CHOLESTEROL BIOSYNTHESIS USING CPR-NULL MICE
AS A MODEL
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CHAPTER TWO: CYTOCHROME P450 REDUCTASE-DEPENDENT ELECTRON
TRANSFER IN THE CHOLESTEROL BIOSYNTHESIS PATHWAY

Introduction
Cholesterol is an important component of the membrane of cells and the precursor
for the synthesis of vitamin D and the various steroid hormones. Recent research shows
that cholesterol has an important role as a signaling molecule for development and
maintaining normal cell functions. The developmental gene sonic hedgehog (Shh) plays
an important role in brain and limb development. This protein has to be covalently linked
to cholesterol for its activity (Roux, Wolf et al. 1997; Lewis, Dunn et al. 2001).
Cholesterol-rich plasma membrane microdomains, termed “membrane rafts” including
caveolae, have been implicated in a variety of cellular processes, including signal
transduction, endocytosis, transcytosis and cholesterol trafficking (Barnett-Norris, Lynch
et al. 2005). Cholesterol plays an important role in maintaining the boundary area and
the properties of the membrane microdomains (Hao, Mukherjee et al. 2001; Maxfield
2002). However, elevated serum cholesterol levels can alter membrane function and
are closely associated with atherosclerotic plaques.
Liver is the primary site for maintaining cholesterol homeostasis, by several
mechanisms including the regulation of cholesterol biosynthesis, uptake through
lipoprotein receptors, release into the blood by lipoproteins, and the storage by
esterification as well as the degradation and the conversion into bile acids (Dietschy,
Turley et al. 1993; Kang and Davis 2000).
Studies performed by Bloch et al in early 1950’s revealed that all the carbon atoms
of cholesterol are derived from acetate. Subsequent investigations elucidated a number
of enzymes and proteins involved in cholesterol biosynthesis and its regulation. In
general, cholesterol biosynthesis pathway can be divided into two segments, an upper
isoprenoid pathway (the mevalonate pathway), and a downstream, or “committed”
pathway, illustrated in Figure 2.1.

Whereas the isoprenoids synthesized in the

mevalonate portion of the pathway are incorporated into many cellular components,
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including proteins and RNA, the downstream pathway, beginning with squalene, is
dedicated specifically to cholesterol biosynthesis in somatic cells.
Cytochrome P450 reductase has a multipart role in sterol synthesis, as shown in
Figure 2.1. In addition to its coupling to squalene monooxygenase, CPR serves as the
redox partner for lanosterol demethylase (CYP51), the enzymatic step that follows the
formation of lanosterol.

CPR can also serve as an alternative electron donor to

cytochrome b5, which is the redox partner for sterol 4α-methyl oxidase and sterol ∆5desaturase (Risley 2002), and CPR may be the redox partner for 7-dehydrocholesterol
reductase, the final step in cholesterol synthesis (Nishino and Ishibashi 2000). In yeast
CPR can be replaced by the NADH-cytochrome b5 pathway (Lamb, Kelly et al. 1999),
but this has not been demonstrated in animals or plants.
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Figure 2.1: A scheme of the cholesterol biosynthetic pathway. Cytochome P450
reductase is suggested to be required for three enzymatic reactions: 1) Squalene

Monooxygenase; 2) Lanosterol 14α-Demethylase; 3) 7-Dehydrocholesterol Reductase.
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Squalene monooxygenase
Squalene monooxygenase (E.C. 1.14.99.7) is a 64-kDa enzyme bound to the
endoplasmic reticulum of eukaryotic cells (Yamamoto and Bloch 1970).

First

characterized by Yamamoto and Bloch in 1970s, squalene monooxygenase catalyzes
the second committed step in cholesterol synthesis from farnesyl pyrophosphate, and
converts squalene to 2,3-oxidosqualene by inserting an oxygen atom across the 2,3double bond, as shown in Figure 2.2.
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Figure 2.2: The squalene monooxygenase reaction.

+ O2
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Assays with microsomal squalene monooxygenase require FAD, NADPH, O2, and
the cytosolic fraction. Although the epoxidation of an alkene is a reaction more typical of
the cytochrome P450s, squalene monooxygenase is not a P450. Squalene
monooxygenase shows no absorption at 450nm and is not inhibited by common P450
inhibitors including carbon monoxide and metyrapone (Yamamoto and Bloch 1970; Ono
and Bloch 1975; Ono, Nakazono et al. 1982). The cytosolic fraction was later found to
contribute three essential components to the enzymatic activity: supernatant protein
factor (SPF), phospholipids, and FAD (Tai and Bloch 1972; Saat and Bloch 1976).
Squalene monooxygenase has a loosely-bound FAD (flavin) group. The addition of
FAD to microsomal reactions reconstituted with purified SPF and phospholipids resulted
in full activation of squalene monooxygenase (Tai and Bloch 1972; Saat and Bloch
1976).
Assays with purified or recombinant squalene monooxygenase require the further
addition of NADPH-cytochrome P450 reductase (CPR) (Ono, Takahashi et al. 1980), an
electron transfer protein more readily recognized for its role as the redox partner for the
microsomal cytochromes P450, a ubiquitous family of hemeprotein monooxygenases
involved in steroid synthesis and drug and xenobiotic metabolism.

The unusual

requirement for an electron transfer partner differentiates squalene monooxygenase
from all other known flavoprotein monooxygenases. Figure 2.3 is a diagram illustrating
the requirement of electron transfer for the squalene monooxygenase reaction.
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Figure 2.3: Diagram representation of squalene monooxygenase reaction:
requirement of electron transfer to the cofactor FAD group.
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The third component of the supernatant fraction required for the monooxygenase
activity is supernatant protein factor (SPF). SPF, a heat-labile cytoplasmic protein, when
added to microsomes along with anionic phospholipids such as phosphatidylserine or
phosphatidylglycerol, was able to activate squalene monooxygenase activity as much
as the cytosolic fraction alone (Tai and Bloch 1972; Saat and Bloch 1976). The cDNA of
SPF was cloned in 2001 by Shibata et al (Shibata, Arita et al. 2001). This protein was
found to belong to the CRAL/TRIO family of lipid-binding proteins that includes Sec14p,
α-tocopherol transfer protein (αTTP), and cellular retinol binding protein (CRALBP)
(Porter 2003). The role of SPF in the squalene monooxygenase reaction remains
unclear. Early studies revealed that SPF did not stimulate squalene monooxygenase
when the enzyme was solubilized. Early work on SPF suggested that it catalyzed the
transfer of squalene into and between intracellular membranes, and that this transfer
enhanced the activity of squalene monooxygenase (Caras, Friedlander et al. 1980;
Friedlander, Caras et al. 1980; Chin and Bloch 1984); Friedlander et al (Friedlander,
Caras et al. 1980) demonstrated that SPF promotes the transfer of squalene from
trypsin-treated microsomes that lack squalene monooxygenase activity to normal,
enzymatically active microsomes in a temperature-dependent process, despite the fact
that SPF binds only weakly to microsomes (Caras, Friedlander et al. 1980). Although
squalene transfer is bidirectional, transfer to membranes containing squalene
monooxygenase is about twice as efficient as that to membranes that lack this enzyme
(Kojima, Friedlander et al. 1981; Fuks-Holmberg and Bloch 1983). Despite these early
studies, it has not been possible to demonstrate high affinity binding of squalene or 2,3oxidosqualene to SPF, and SPF shows greatest affinity for phosphatidylinositol and αtocopherylquinone (Panagabko, Morley et al. 2003; Stocker and Baumann 2003). The
dependency of squalene monooxygenase on anionic phospholipids for maximal activity
raises the possibility that an anionic phospholipid, such as phosphatidylinositol, is the
physiologic ligand for SPF (Tai and Bloch 1972; Chin and Bloch 1984). The mechanism
by which SPF stimulates microsomal squalene monooxygenase remains unknown.
Studies have shown that SPF also activates the other enzymes involved in cholesterol
synthesis including oxidosqualene cyclase and HMG-CoA reductase (Saat and Bloch
1976; Mokashi, Singh et al. 2005). Oxidosqualene cyclase converts the product of
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squalene monooxygenase, 2,3-oxidoqualene, to the first sterol in the pathway,
lanosterol. HMG-CoA is the major regulatory step for cholesterol biosynthesis pathway.
Early studies revealed that the SPF and phospholipids could be replaced by the
nonionic detergent Triton X-100, which has been used in most in-vitro squalene
monooxygenase activity assays. It was proposed that Triton X-100 solubilizes the
microsomes and removes the requirement for intermembrane or intramembrane
squalene transport (Tai and Bloch 1972).
The expression of squalene monooxygenase is highly regulated transcriptionally
by cholesterol. Nagia et al (Nagai, Sakakibara et al. 2002; Ono 2002) identified the
sterol regulatory element (SRE) sequence and nuclear factor Y (NF-Y) binding
sequence in the promoter of the gene of squalene monooxygenase, both of which play
a critical role in sterol-mediated regulation of the gene. They showed that the sterol
regulatory element-binding protein (SREBP-2) activates transcription of the gene.
SREBP and its regulatory proteins are found in the endoplasmic reticulum and require
proteolysis to be released from the membrane to find its way into the nucleus where it
can upregulate transcription of cholesterologenic genes (Brown and Goldstein 1997).
Lanosterol 14α-demethylase
More than 1000 genes of the cytochrome P450 superfamily are found in species of
all of the kingdoms of biology. CYP51, encoding lanosterol 14α-demethylase, is the only
known P450 expressed in prokaryotes and eukaryotes and considered to be an
ancestor of the P450 superfamily (Nelson 1999).
Lanosterol 14α-demethylase catalyzes the oxidative removal of the 14α-methyl
group of lanosterol and 24-methylene-24,25-dihydrolanosterol in yeast and fungi,
obtusifoliol in plants, and 24,25-dihydrolanosterol in mammals to give α14,15-desaturated
intermediates in ergosterol, phytosterol, and cholesterol biosynthesis, respectively.
During the catalytic cycle lanosterol undergoes three successive monooxygenation
reactions: The methyl group is first converted to an alcohol, then to an aldehyde, and
then removed as formic acid without the release of the substrate, each step requiring
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one molecule of molecular oxygen and one molecule of NADPH (Rozman and
Waterman 1998), as illustrated in Figure 2.4.
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Figure 2.4: The lanosterol 14α-demethylase reaction. The methyl group is removed
by a three-step process catalyzed by lanosterol 14α-demethylase (CYP51) without
release of intermediates. Each step requires cytochrome P450 reductase (CPR) and
one molecule of oxygen.
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In animals, lanosterol 14α-demethylase is the only P450 in the cholesterol
synthesis pathway. Its activity is strongly inhibited by carbon monoxide and azole
compounds. Lanosterol 14α-demethylase is a housekeeping gene expressed in virtually
all animal cells with high expression level in the liver, the site for cholesterol synthesis.
However, the highest level of expression of lanosterol 14α-demethylase was found in
testes. This is because the product of lanosterol 14α-demethylase is the potent meiosisactivating sterol, 4,4-dimethylcholesta-8(9),14,24-trien-3β-ol (also known as FF-MAS)
(Rozman and Waterman 1998).
Like other cholesterolgenic genes, lanosterol 14α-demethylase responds to
cholesterol negative feedback regulation through binding of SREBPs to a sterol
regulatory element (SRE) in the CYP51 promoter region. Similar to squalene
monooxygenase, the predominant SREBP-isoform responsible for regulation of CYP51
expression in mammalian cells is SREBP-2 (Rozman, Fink et al. 1999; Fon Tacer,
Kalanj-Bognar et al. 2003). The CYP51 promoter also contains a cAMP regulatory
element (CRE) known to bind cAMP regulatory proteins CREB/CREM. The CYP51
response to cAMP has been observed to be independent of lipid composition and might
play a role in cross-talk of cholesterol biosynthesis with other important biological
processes (Rozman, Fink et al. 1999; Halder, Fink et al. 2002). In hepatic cytochrome
P450 reductase-null mice, the expression level of lanosterol 14α-demethylase increased
by 2-fold (Wang, Chamberlain et al. 2005; Weng, DiRusso et al. 2005).
The structure of lanosterol 14α-demethylase in M. tuberculosis was solved by
Podust et al in 2001. Lanosterol 14α-demethylase exhibits the typical P450 fold but
contains differences that define the substrate access channel which runs roughly
parallel to the cofactor heme (Podust, Poulos et al. 2001). Like many other cytochrome
P450s, the activity of human lanosterol 14α-demethylase requires cytochrome P450
reductase. However, it has been reported that the activity of lanosterol 14α-demethylase
was augmented by the membrane-bound cytochrome b5 in an in vitro reconstituted
system in the presence of cytochrome P450-reductase (Lamb, Kaderbhai et al. 2001).
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7-Dehydrocholesterol reductase
7-Dehydrocholesterol reductase (E.C. 1.3.1.21), the final enzyme of cholesterol
synthesis, catalyzes the reduction of the ∆7 double bond of 7-dehydrocholesterol and 7dehydrodesmosterol to yield cholesterol and desmosterol, respectively, as shown in
Figure 2.5. Desmosterol is a 27-carbon sterol that differs from cholesterol due to the
presence of a C24–25 double bond in the side chain, which is reduced by 24-sterol
reductase to generate the end product cholesterol (Waterham and Wanders 2000).
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Figure

2.5: Terminal

enzymatic

reactions

in

cholesterol

synthesis.

7-

Dehydrocholesterol reductase (7DHCR) reduces the C7–8 double of bond of both 7dehydrocholesterol and 7-dehydrodesmosterol to yield cholesterol and desmosterol,
respectively. NADPH is required for the reaction. 24-Sterol reductase reduces the C24–
25 double bond in desmosterol to yield cholesterol.
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Shefer et al. (Shefer, Salen et al. 1998) characterized the substrate specificity of 7dehydrocholesterol reductase. Although less efficient than the reduction of 7dehydrocholesterol, this group demonstrated that 7-dehydrocholesterol reductase can
reduce the C7–8 double bond in the B-ring of ergosterol, 7-dehydrositosterol, and 7dehydroepicholesterol. Ergosterol reduction to brassicasterol has been used as a
surrogate assay for the activity of the enzyme in both reconstituted microsomes and in
cell cultures (Honda, Tint et al. 1996; Honda, Tint et al. 1998; Shefer, Salen et al. 1998).
Although experimental data on the membrane topology of 7-dehydrocholesterol
reductase is unavailable, it has been proposed to be a multi-transmembrane protein
located in endoplasmic reticulum, based on the predicted amino acid sequence. Fitzky
et al. (Fitzky, Moebius et al. 2001) predicted a model with nine transmembrane
spanning domains containing the putative sterol-sensing domain (Fitzky, Moebius et al.
2001). Waterham and Wanders (Waterham and Wanders 2000) proposed a more
conservative model with six transmembrane spanning domains which differs from
Fitzky’s model in orientation of the carboxy terminus relative to the cytosol, and in the
localization of the extramembranous (Waterham, Wijburg et al. 1998). The potential
sterol-sensing domain (SSD) in rat and human 7-dehydrocholesterol reductase has high
homology with the SSD of sterol cleavage activating protein (SCAP). SSDs have been
identified in a number of other proteins, including HMG-CoA reductase, sterol cleavage
activating protein, and Niemann–Pick type C protein. All of these proteins are involved
in cholesterol synthesis or homeostasis (Bae, Lee et al. 1999; Fitzky, Moebius et al.
2001), whereas the SCAP motif binds sterols is essential for the cleavage of SREBP to
release the nuclear transcriptional factor to activate the sterol regulating genes (Brown
and Goldstein 1997).
The conversion of 7-dehydrocholesterol to cholesterol requires NADPH which
cannot be substituted by NADH as a reducing factor. It has been reported that the
presence of molecular oxygen was not necessary for the conversion of 7dehydrocholesterol to cholesterol in rat liver homogenate, indicating cytochrome P450 is
not involved. Wilton et al. (Wilton, Munday et al. 1968) purposed that there was a direct
transfer of hydrogen from NADPH to the 7α-position of cholesterol, and that the 8βhydrogen was derived from water.
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It has also been suggested that cytochrome-P450 reductase activity is required for
the enzyme to catalyze reduction of 7-dehydrocholesterol in a reconstituted microsomal
system; however, this reaction mechanism is distinct from that of cytochrome P450s.
Specific inhibitors of the cytochrome P450s, carbon monoxide and azole compounds,
had no effect on the activity of 7-dehydrocholesterol reductase (Nishino and Ishibashi
2000). EDTA, o-phenanthroline and KCN inhibited the activity of the enzyme, indicating
the requirement of a metal ion for the enzymatic reaction (Nishino and Ishibashi 2000).
Nishino et al further reported that ferric ion restored the reductase activity in EDTAtreated microsomes, suggesting that 7-dehydrocholesterol reductase may be an ironcontaining enzyme. Studies done by Scallen et al (Scallen, Noland et al. 1985)
suggested that sterol carrier protein 2 (SCP2) activates the conversion of 7dehydrocholesterol to cholesterol. It also has been suggested that SCP-2 is necessary
to transfer certain water-insoluble cholesterol precursors and metabolic products
between one compartment and the next compartment in a cascade of enzyme
reactions. It has been suggested SCP2 binds 7-dehydrocholesterol and may increase
substrate availability to the reductase (Scallen, Noland et al. 1985).
Shefer et al (Shefer, Salen et al. 1998) suggested that the activity of 7dehydrocholesterol reductase is regulated by phosphorylation/dephosphorylation. In the
reconstituted liver microsomal system, addition of alkaline phosphatase resulted in
decreased 7-dehydrocholesterol reductase activity, whereas treatment with NaF, a nonspecific phosphatase inhibitor, increased the activity of the enzyme. In vivo regulation of
7-dehydrocholesterol reductase activity by phosphorylation/dephosphorylation has not
been demonstrated. Multiple potential phosphorylation sites are predicted in 7dehydrocholesterol reductase based on amino acid sequence of this protein. Bae et al.
(Bae, Lee et al. 1999) identified multiple potential protein kinase C phosphorylation and
potential tyrosine kinase phosphorylation sites in rat 7-dehydrocholesterol reductase,
some of those are conserved in the human, murine, rat, and zebrafish proteins. The
potential tyrosine phosphorylation site corresponding to amino acids 450–458 is
contained within the sterol reductase 2 motif in rat 7-dehydrocholesterol reductase. The
sterol reductase 2 motif also exists in the yeast genes involved in ergosterol synthesis
(Correa-Cerro and Porter 2005).
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As expected for enzymes involved in cholesterol synthesis, the expression of 7dehydrocholesterol reductase is induced by sterol deprivation. Bae et al (Bae, Lee et al.
1999) identified a sterol regulatory element (SRE) sequence and two nuclear factor Y
(NF-Y) binding sequences in the promoter of the gene for 7-dehydrocholesterol
reductase, indicating sterol mediated regulation of the gene (Bae, Lee et al. 1999). A
deficiency of 7-dehydrocholesterol reductase activity because of genetic mutation in
humans has recently been found to cause Smith-Lemli-Opitz syndrome (SLOS). SLOS
is an autosomal recessive disorder with various developmental abnormalities and is
characterized by elevated 7-dehydrocholesterol in serum body fluids and tissues
(Correa-Cerro and Porter 2005).
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Experimental rationale
Cytochrome P450 reductase has a multipart role in sterol synthesis.

In

reconstituted microsomal systems, cytochrome P450 reductase appears to be required
for three enzymatic reactions in cholesterol synthesis pathway. It has been reported that
cytochrome P450 reductase was essential for the activity of solubilized squalene
monooxygenase by Triton X-100 (Ono, Ozasa et al. 1977). Cytochrome P450 reductase
serves as the redox partner for lanosterol demethylase (CYP51), the enzyme that
removes the 14-methyl group from lanosterol. Cytochrome P450 reductase may also
serve as the redox partner for 7-dehydrocholesterol reductase, the final step in
cholesterol synthesis (Nishino and Ishibashi 2000). In yeast CPR can be replaced by
the NADH-cytochrome b5 pathway (Lamb, Kelly et al. 1999), but this has not been
demonstrated in animals or plants. In conditional-null mice, in which the CPR gene is
deleted in the liver during maturation, adult animals exhibit an 80% decrease in plasma
cholesterol levels and accumulation of lipid droplets in the livers, suggesting a loss in
the ability to synthesize cholesterol and accumulation of intermediate(s) in the liver.
Given that the three enzymes proposed to require cytochrome P450 reductase have no
structural similarity and contain different cofactors (squalene monooxygenase is a FADdependent enzyme, lanosterol demethylase is a heme-binding protein, and the cofactor
of the intergral membrane protein 7-dehydrocholesterol reductase is unknown), the
purpose of this study is to determine if additional electron transfer partner(s) exist for the
above-mentioned enzymes. The cytochrome P450 reductase-null mouse is an excellent
model to study alternative electron transfer for these enzymes in cholesterol
biosynthesis.
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Specific Aims
Specific Aim 1: Determine if cytochrome P450 reductase is required for the activity of
squalene monooxygenase in cholesterol biosynthesis.

Squalene monooxygenase

requires a second enzyme to provide the electrons necessary for catalysis, and for
many years it has been assumed that cytochrome P450 reductase (CPR) is this
requisite electron donor protein. The possibility that additional electron transfer partners
might exist for squalene monooxygenase has not been explored. The objective of this
project is to determine if other redox proteins can substitute for CPR in hepatic CPR-null
mice. Squalene monooxygenase activity will be determined by 2,3-oxidosqualene
formation from

14

C-squalene in the presence of an oxidosqualene cyclase inhibitor (to

prevent feed-through of the product). Squalene and 2,3-oxidosqualene formation will be
monitored in hepatocytes using

14

C-mevalonate as the precursor. Oxidosqualene

formation will demonstrate that the reductase is functional in whole cells, and, when
compared to oxidosqualene formation in wild-type cells, will give an indication of the
extent to which it contributes to squalene monooxygenase activity.
Specific Aim 2: Determine if the cytochrome P450 reductase is required in other steps,
including lanosterol demethylase and 7-dehydrocholesterol reductase, in the cholesterol
biosynthesis pathway. To determine if CPR is an essential component of cholesterol
synthesis,

14

C-mevalonate incorporation into cholesterol will be measured in

hepatocytes isolated from CPR-null mice; if cholesterol synthesis is blocked, the CPRdependent enzyme will be identified from the intermediate that accumulates in these
cells. To determine if CPR participates in the specific enzyme reactions noted above,
the activities of these enzymes will be determined in CPR-null microsomes and in
hepatocytes.

Copyright © Li Li 2006
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CHAPTER THREE: MATERIALS AND METHODS
Animals
CPR liver-specific knockout mice (Alb-Cre+/–/Cprlox+/+) were generated by crossing
mice expressing liver-specific Cre under control of the an albumin promoter (Alb-Cre)
with two lines of mice bearing a conditional CPR allele (Cprlox+/+) (Gu, Weng et al. 2003;
Wu, Gu et al. 2003). Littermates lacking the Alb-Cre transgene (Alb-Cre–/–/Cprlox+/+) were
designated as wild-type. Two to four month old mice from null and wild-type littermate
groups on mixed C57BL/6 (75%) and 129/Sv (25%) genetic background were used in
the studies. Animals were normally maintained in a temperature-, humidity-, and lightcontrolled facility (70-72°F, 48-52% humidity, 12-hr light/dark cycle) and were allowed
free access to water and food. Animal-use protocols were approved by the Institutional
Animal Care and Use Committee of the University of Kentucky.
Preparation of microsomal and cytosolic fractions
Animals were killed by CO2 asphyxia, the livers promptly removed, and microsomal
and cytosolic fractions were prepared by standard procedures (Singh, Mokashi et al.
2003). In brief, approximately 3 livers were minced thoroughly with scissors, transferred
into 4 volumes by sample weight of chilled homogenization buffer (100 mM Tris-HCl
buffer, pH 7.4, containing 1.0 mM EDTA) and homogenized using a homogenizer. All
subsequent steps were carried out at 4 °C. The samples then were centrifuged at
10,000g for 20 min. The supernatant was collected and centrifuged at 100,000g in for
60 min. The upper lipid layer was removed and the cytosolic supernatant collected. The
microsomal pellet was resuspended in chilled homogenization buffer (100mM Tris-HCl
buffer, pH 7.4, containing 1.0 mM EDTA) and the 100,000g centrifugation for 60 min
was repeated. The microsomal fraction was resuspended at ~15 mg of protein/ml in
100 mM Tris-HCl, 1mM EDTA, (pH 7.4) and the cytosolic fraction (100,000xg
supernatant) was diluted to ~15 mg of protein/ml. Protein content was determined by
Coomassie Plus assay reagent kit (Pierce). Samples were stored at
32

80°C.

Expression and purification of human supernatant protein (SPF)
The human SPF cDNA was cloned and expressed in the pTYB4 expression vector
(New England Biolabs). SPF protein was purified following the protocol for expression of
intein fusion proteins with the IMPACT T7 system as follows. SPF expression was
induced in E. coli ER2566 cells overnight with 1 mM isopropyl-α-thiogalactopyranoside
at 30 °C with slow shaking. All subsequent steps were carried out at 4 °C. Cells were
broken in a French pressure cell in buffer containing 20 mM Tris-HCl (pH 7.4), 500 mM
NaCl, and 0.1 mM EDTA, and the lysate was cleared by 12,000 × g centrifugation for 30
min followed by digestion with 1 µg of DNA nuclease for 1 h. The cleared lysate was
loaded onto a chitin affinity column (2-ml bed volume), washed with 40 ml of lysis buffer,
and incubated overnight at 4 °C in 4 ml of buffer containing 30 mM β-mercaptoethanol
to promote cleavage of the intein-SPF bond. SPF was eluted with 10-20 ml of the same
buffer, which was then replaced by centrifugal dialysis with 20 mM Tris-HCl, pH 7.4, and
the sample was stored at 80 °C. The purified protein retains four amino acids (Leu-GluPro-Gly) at the C terminus that are derived from the intein fusion.
Squalene monooxygenase assays
Microsomal squalene monooxygenase activity was determined with mouse liver
microsomes (400 µg/incubation) in a final volume of 0.2 ml as described previously
(Singh, Mokashi et al. 2003). In brief, 400 µg of microsomal protein, 30 µM FAD, 40 µM
[14C]squalene, 10 µg of phosphatidylglycerol, and 0.3 mM AMO 1618 (Calbiochem) to
inhibit oxidosqualene cyclase in 200 µl of 20 mM Tris-HCl buffer, pH 7.4, with 1 mM
EDTA. Reactions were started by the addition of NADPH to 1 mM, incubated in a 37 °C
water bath for 1 h, and were stopped by the addition of 0.5 ml of 10% KOH in methanol
after the incubation volume was brought to 1 ml with water. The tubes were capped,
and after saponification at 80 °C for 1 h the neutral lipids were extracted with 3 ml of
petroleum ether. After removing the solvent by centrifugal evaporation, the lipids were
resuspended in 50 µl of petroleum ether and spotted onto silica thin-layer plates. Lipids
were fractionated with 5% ethyl acetate in hexane, visualized, and quantified by
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electronic autoradiography (Packard Instant Imager). Purified recombinant SPF was
added at 0.8 µg unless indicated otherwise.

Radiolabeled

14

C-squalene was

synthesized by SRI International (Menlo Park, CA) and used at 7 mCi/mmol.
Affinity chromatography of SPF to nucleotide affinity resins
To determine the binding of SPF to nucleotide affinity resins, 4 µg of SPF in 40 µl
of 50 mM potassium phosphate buffer, pH 7.5, was mixed with approximately the same
volume of 2’,5’-ADP-agarose or β-NADP-agarose and incubated at room temperature
for 10 min. The resin was pelleted in a microfuge, the supernatant removed, and the
resin washed 3 times with 0.5 ml of buffer. Elution was carried out with 40 µl of 10 mM
NADPH or FAD in phosphate buffer. All supernatant fractions were analyzed by SDSpolyacrylamide gel electrophoresis with immunoblotting as described below.
Isolation of primary hepatocytes
Hepatocytes were prepared from 12-16-week old mice as follows:

Mice were

anesthetized with urethane and the liver was perfused via the portal vein with 50 ml of
liver perfusion medium (Gibco) followed by 30 ml of liver digestion medium (Gibco).
The liver was removed and transferred into a tissue culture plate and the liver capsule
was removed.

Hepatocytes were dissociated by blunt dissection and twice-filtered

through a double layer of gauze. The cells were pelleted, washed twice, counted, and
viability determined by trypan blue exclusion. Hepatocytes were allowed to attach to
35-mm tissue culture plates (BD Primaria™) in William’s E Medium supplemented with
10% fetal bovine serum, 4 mM L-glutamine, 100 units/ml penicillin, and 100 µg/ml
streptomycin sulfate. After 3 hr the cells were washed, the medium replaced with fresh
medium, and the cells were used immediately in radiolabeling assays or incubated
overnight prior to cytological analysis. Lipids were visualized by fixing the hepatocytes
in 10% formalin and staining with hematoxylin-eosin and oil red O following standard
procedures.
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Radiolabeling of squalene, 2,3-oxidosqualene, and cholesterol in primary
hepatocytes
Primary hepatocytes, prepared as described above, were incubated for 3 hr in
media to which 1 µCi/ml of

14

C-mevalonate was added, after which the cells were

washed twice with phosphate-buffered saline, harvested by scraping, resuspended, and
lysed by sonication in 1 ml 0.05 M Tris-HCl (pH 7.5) buffer. Inhibitors of cholesterol
synthesis were added to the media prior to the addition of radiolabel as indicated in the
figure legends: AMO 1618 (Calbiochem), 1.5 mM; terbinafine (TCI America), 60 µM;
ketoconazole (Sigma Chemical), 10 µM; squalestatin (zaragozic acid A, Sigma
Chemical), 66 µM. Radiolabeled squalene and 2,3-oxidosqualene were extracted and
quantified

by

electronic

autoradiography

as

described

above

for

squalene

monooxygenase assays. Cholesterol synthesis was measured as follows: Lipids were
extracted into chloroform:methanol (2:1), the solvent was removed by evaporative
centrifugation, and the lipids were resuspended and spotted onto silica thin layer plates.
Chromatography was carried out in petroleum ether:ethyl ether:acetic acid (60:40:1),
lipids were identified by co-chromatography of authentic standards visualized by iodinevapor staining, and quantified by electronic autoradiography.
Extraction of lipids and gas chromatographic-mass spectrometric analysis
Lipids from hepatocytes incubated in the absence of radiolabel were prepared as
described above, fractionated by thin-layer chromatography, and visualized by iodinevapor staining.

The desired lipid was scraped from the plate, extracted into

chloroform:methanol (2:1), dried, and derivatized with trimethylsilane. For the analysis
of lipids from the livers of wild-type and CPR-/- mice, 20 mg of liver tissue was
homogenized in 1 ml of water, followed by the addition of 2 ml of alcoholic potassium
hydroxide (4.5 M KOH in 60% ethanol) and the samples were saponified at 90°C for 1
h. The samples were diluted with 1 ml of 95% ethanol and saponification continued for
1 hr, after which the lipids were extracted into 5 ml of n-heptane, dried by centrifugal
evaporation, and derivatized with trimethylsilane. Mass spectra were acquired by the
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University of Kentucky Mass Spectrometry Facility. GC-MS was performed on a Trace
Gas Chromatograph with a DB5-ms (Agilent/J&W) 30 m x 0.25 mm (0.25 µm df) column
coupled to a ThermoFinnigan PolarisQ ion-trap mass spectrometer. Electron impact
ionization mass spectra were recorded at 70 eV and a mass spectral search program
was used to identify compounds. Authentic 24-dihydrolanosterol (Steraloids, Inc.) was
used to confirm the lipid assignment.
7-Dehydrocholesterol reductase assay
Microsomes (800 µg of protein) were incubated in a final volume of 500 µl buffer
(pH 7.3) containing 100 mM K2HPO4, 1 mM DTT, 30 mM nicotinamide, 0.1 mM EDTA
and NADPH generating system: 3.4 mM NADP+, 30 mM glucose-6-phosphate, 0.3 IU
glucose-6-phosphate dehydrogenase and ergosterol solubilized with 15 µl of a 13%
solution of ß-cyclodextrin (Pharmatec Inc., Alachua, FL). The reaction was initiated by
the addition of NADPH regenerating system and continued for 1hr at 37°C with vigorous
shaking. The reaction was stopped by adding 1ml of 1 N ethanolic NaOH and 500 ng of
stigmasterol as an internal recovery standard. Stigmasterol (24-ethylcholest-5,22-diene3β-ol) is a plant sterol which is not synthesized by humans and is identical to
brassicasterol except that it has an ethyl instead of a methyl group at C-24. The mixture
was saponified at 90°C for 1hr, extracted with 3 ml n-hexane and evaporated under a
stream of nitrogen. Trimethylsilyl-ether derivatives were formed for gas–liquid
chromatography–mass spectrometry. Quantitation was carried out by gas–liquid
chromatography–mass spectrometry with selected-ion monitoring (SIM) using a
ThermoFinnigan PolarisQ ion-trap mass spectrometer. Mass spectra were acquired by
the University of Kentucky Mass Spectrometry Facility. GC-MS was performed on a
Trace Gas Chromatograph with a DB5-ms (Agilent/J&W) 30 m x 0.25 mm (0.25 µm df)
column coupled to a ThermoFinnigan PolarisQ ion-trap mass spectrometer. Electron
impact ionization mass spectra were recorded at 70 eV and a mass spectral search
program was used to identify compounds. The multiple ion detector was focused on m/z
363 for ergosterol, m/z 380 for brassicasterol, and m/z 484 for 7-dehydrositosterol.

36

Gel electrophoresis and immunoblotting
Microsomal or cytosolic proteins were separated by sodium dodecyl sulfatepolyacrylamide gel electrophoresis on 10% gels and electroblotted to nitrocellulose
filters.

Immunodetection was carried out with goat anti-rabbit cytochrome P450

reductase, rabbit anti-human squalene monooxygenase, or chicken anti-human SPF as
the primary antibody and alkaline phosphatase-conjugated IgG as the secondary
antibody.

Proteins were visualized by bromochloroindolyl phosphate/nitro-blue

tetrazolium staining. Reductase antibody was a gift from Dr. M. J. Coon (University of
Michigan); antibodies to squalene monooxygenase and SPF were prepared by
commercial suppliers to the purified recombinant proteins provided by our laboratory.
For immunoquantitation, 25 µg of protein was fractionated by electrophoresis and
electroblotted to nitrocellulose. The membrane was blocked with 0.05% Tween-20 and
5% defatted milk and then incubated in this same buffer with antibody to squalene
monooxygenase, SPF, or HMG-CoA reductase (Upstate USA, Inc., or Santa Cruz
Biotechnology, Inc.).
conjugated

to

The immunoblots were developed with a secondary antibody

horseradish

peroxidase

and

visualized

and

quantified

by

chemiluminescence (Supersignal West Pico Chemiluminescent Substrate, Pierce) on a
Kodak Image Station.

Copyright © Li Li 2006
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CHAPTER FOUR: RESULTS AND CONCLUSION
The cytochrome b5 pathway does not support squalene monooxygenase in
mouse liver microsomes
Gene deletion studies revealed that CPR is not essential to ergosterol synthesis in
yeast (Sutter and Loper 1989), and subsequent studies demonstrated that the three
enzymes thought to be dependent on CPR, squalene monooxygenase, lanosterol 14αdemethylase (CYP51) and sterol ∆22-desaturase (CYP61), could be supported
efficiently by the microsomal NADH-dependent cytochrome b5 electron transport
pathway (Lamb, Kelly et al. 1999).

To determine if the b5 pathway was similarly

effective in mammalian cells, we monitored 2,3-oxidosqualene synthesis in liver
microsomes from hepatic CPR-/- mice. As shown in Figure 4.1, only NADPH supported
squalene monooxygenase activity, and only in microsomes from wild-type mice; neither
NADPH nor NADH supported squalene monooxygenase activity in microsomes from
animals lacking CPR. These results indicate that, unlike in yeast, the cytochrome b5
pathway cannot support squalene monooxygenase in mouse liver. This conclusion was
also reached by Ono and Bloch (Ono and Bloch 1975) in studies with partially purified
enzymes.
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Figure

4.1:

The

cytochrome

b5

pathway

monooxygenase in mouse liver microsomes.

does

not

support

squalene

Squalene monooxygenase activity

was measured in microsomes prepared from livers of CPR-/- or wild-type animals in the
presence of Triton X100 and NADPH or NADH. Lane1: CPR-/- liver microsomes in the
presence of 1 mM NADPH ; Lane 2: CPR-/- liver microsomes in the presence of 1 mM
NADH; Lane 3: Wild-type liver microsomes in the presence of 1 mM NADPH; Lane 4:
Wild-type liver microsomes in the presence of 1 mM NADH.

39

Addition of cytosol supports activity of squalene monooxygenase in
CPR-/- microsomes
Studies have shown that squalene monooxygenase requires the cytosolic fraction
for its activity. The non-ionic detergent Triton X100 can replace supernatant protein
factor (SPF). It has been shown that non-ionic detergent Triton X-100 effects enzymatic
reactions in a complex manner and that the detergent can activate some reactions and
inhibit the others. To exclude the inhibitory effects of Triton X-100 on the possible
alternative reductase and the possibility of a cytosolic reductase in liver, the 100,000xg
supernatant fraction was added back to microsomes from CPR-/- and wild-type animals.
Addition

of

cytosol

from

CPR-/-

either

or

wild-type

animals

to

CPR-/- microsomes in the presence of NADPH but not NADH restored up to 40% of the
squalene monooxygenase activity seen in wild-type microsomes (Figure 4.2).
Essentially no activity is obtained with CPR-null microsomes in the absence of cytosol
and NADPH, indicating a requirement for cytosol and NADPH-dependence. In addition,
virtually no cytochrome P450 reductase exists in cytosol fraction, as detected by
Western blotting for cytochrome P450 reductase (Figure 4.3), suggesting this
stimulation is not due to residual cytochrome P450 reductase in cytosol fraction. Cytosol
can not be replaced by Triton X-100 in CPR-/- microsomes, suggesting that it is
inhibitory effect on the unknown reductase for squalene monooxygenase. Western blot
analysis also shown at least a 95% reduction in CPR expression in CPR-null
microsomes, as shown in Figure 4.3, similar to the results performed by Gu et al. (Gu,
Weng et al. 2003). Total CPR-deletion in CPR-null livers was not expected to occur
since this tissue also contains several other cell types besides hepatocytes such as liver
endothelial cells and Kupffer cells.
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Figure 4.2: Stimulation of squalene monooxygenase activity in mouse liver
microsomes upon addition of cytoplasmic fraction.

Squalene monooxygenase

activity was measured in CPR-/- or wild-type liver microsomes (400 µg total protein) in
the presence of 1 mM NADPH. Lane1: CPR-/- liver microsomes; Lane 2: CPR-/- liver
microsomes and CPR-/- liver cytosol (2 mg total protein); Lane 3: CPR-/- liver
microsomes and wild-type liver cytosol (2 mg total protein); Lane 4: Wild-type liver
microsomes; Lane 5: Wild-type liver microsomes and wild-type liver cytosol (2 mg total
protein).
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Figure 4.3: Levels of CPR expression in cytoplasmic and microsomal fractions
determined by immunoblotting with microsomes and cytosols. Lane 1: Prestaining
protein marker; Lane 2: CPR standard (purified protein, 1 µg); Lane 3: 20 µg of total
protein from CPR-/- mouse liver microsomes (upper panel) or cytosol (lower panel);
Lane 4: 20 µg of total protein from wild-type mouse liver microsomes (upper panel) or
cytosol (lower panel).

Immunodetection was carried out with goat anti-rabbit

cytochrome P450 reductase as the primary antibody and alkaline phosphataseconjugated

IgG

as

the

secondary

antibody.

Proteins

bromochloroindolyl phosphate/nitro-blue tetrazolium staining.

1

2

3
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4

were

visualized

by

An SPF-dependent squalene monooxygenase reductase is present in CPR-/microsomes
Squalene monooxygenase activity measured in hepatic CPR-null microsomes
showed a dose-dependent pattern with CPR-null liver cytosol (Figure 4.4A). Although
initially this suggested the presence of a cytosolic reductase, further studies suggested
that this activity is due to the presence of SPF, a cytosolic protein that stimulates
squalene monooxygenase, HMG-CoA reductase, and cholesterol synthesis (Tai and
Bloch 1972; Ferguson and Bloch 1977; Mokashi, Singh et al. 2005). The addition of
purified recombinant SPF to CPR-null microsomes abolished the dose-dependent
response of squalene monooxygenase activity versus the concentrations of cytosol
proteins (Figure 4.4B).
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Figure 4.4: Addition of supernatant protein factor (SPF) abolished the dosedependent

response

of

squalene

monooxygenase

activity

versus

the

concentrations of cytosol proteins. A) Squalene monooxygenase activity was
measured in hepatic CPR-null microsomes in dose-dependent pattern with CPR-null
liver cytosol proteins. B) Squalene monooxygenase activity was measured in hepatic
CPR-null microsomes with various concentrations of CPR-null liver cytosol proteins in
the presence of bacterial expressed purified SPF (0.8ug). Squalene monooxygenase
activity was measured with CPR-null liver cytosol proteins. Each point represents the
mean and standard error of 3 experiments carried out in duplicate.
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Furthermore, we demonstrated that the addition of purified recombinant SPF to
microsomes from CPR-/- or wild-type animals increased squalene monooxygenase
activity by 2-4-fold. This increase is similar to that seen upon the addition of cytosol to
CPR-/- microsomes, but is somewhat less than the stimulation obtained with 0.1% Triton
X100 in wild-type microsomes.

This detergent is unable to stimulate squalene

monooxygenase activity in microsomes from CPR-/- animals even in the presence of
SPF, suggesting that the stimulatory effect of this detergent is on CPR.

SPF was

considerably less effective in stimulating squalene monooxygenase when NADH was
the reductant, further suggesting that the squalene monooxygenase reductase was
NADPH-specific (Figure 4.5).
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Figure 4.5: An SPF-dependent squalene monooxygenase reductase is present in
CPR-/- microsomes. Squalene monooxygenase activity was measured in CPR-/- liver
microsomes in the presence of NADPH or NADH and Triton X-100 (TX100) or purified
recombinant SPF ( 0.8 µg).

Each value represents the mean ± S.E. of three

experiments carried out in duplicate.
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SPF is not involved in NADPH-binding
To exclude the possibility that SPF was serving as the NADPH-dependent
reductase, SPF was added to purified, recombinant squalene monooxygenase: no
squalene monooxygenase activity was obtained in this reconstituted system in the
absence of CPR. Addition of SPF to detergent-activated wild-type microsomes also
provided no additive effect.

Affinity chromatography experiments provided further

evidence against a redox role for SPF, as SPF did not bind to 2’,5’-ADP agarose or βNADP-agarose, and washing with NADPH or FAD did not elute SPF protein (Figure
4.6). Consistent with this finding, SPF shows no structural features characteristic of
NADPH-dependent reductases (Stocker, Tomizaki et al. 2002).
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Figure 4.6: The binding of SPF to nucleotide affinity resins. 4 µg of purified SPF
was mixed with 2’,5’-ADP-agarose or β-NADP-agarose affinity resin and incubated at
room temperature for 10 min. The resin was pelleted in a microfuge, the supernatant
removed, and the resin washed. Elution was carried out with 40 µl of 10 mM NADPH or
FAD in phosphate buffer.

All supernatant fractions were analyzed by SDS-

polyacrylamide gel electrophoresis with immunoblotting. Lane 1: Molecular markers;
Lane 2: Elution of 2’,5’-ADP-agarose resin with FAD; Lane 3: Elution of 2’,5’-ADPagarose resin with NADPH; Lane 4: Supernatant from the incubation with 2’,5’-ADPagarose resin; Lane 5:Purified SPF; Lane 6: Supernatant from the incubation with βNADP-agarose resin;

Lane 7: Elution of β-NADP-agarose resin with FAD; Lane 8:

Elution of β-NADP-agarose resin with NADPH.

49

Antibody to P450 reductase does not block the SPF-dependent reductase
Because conditional-null animals often have very low levels of the targeted gene
product due to incomplete deletion during development, as well as due to expression in
other cell types (i.e., macrophages, vascular tissue), the possibility was considered that
the activity present in CPR-null hepatic microsomes was due to low levels of CPR from
other sources. To exclude this possibility that residual CPR might play a role in the
SPF-dependent squalene monooxygenase activity, antibodies to CPR were added to
microsomes from wild-type and CPR-null animals, and squalene monooxygenase
activity was measured in the presence of SPF. As shown in Figure 4.7, antibody to CPR
reduced squalene monooxygenase activity in wild-type microsomes by more than 60%,
to a level equal to that obtained with microsomes from CPR-/- animals. Antibody to CPR
had no effect on squalene monooxygenase activity in CPR-/- animals, demonstrating
that residual CPR was not responsible for the activity present in these preparations.
Addition of antibody to cytochrome P450 2E1 had no effect on activity in either
microsomal preparation, ruling out a nonspecific effect of antibody on squalene
monooxygenase activity, and greater amounts of antibody to CPR had no further effect
on activity in either preparation.

These results indicate that residual CPR in

microsomes from CPR-/- animals is not responsible for the squalene monooxygenase
activity seen in these preparations.
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Figure 4.7: Antibody to P450 reductase does not block the SPF-dependent
reductase. Squalene monooxygenase activity was measured in CPR-/- or wild-type
liver microsomes in the presence of cytosol and 0.2 mg/ml polyclonal antibody to CPR
or to cytochrome P450 2E1 (CYP2E1). Antibodies were added to the incubations 30
min prior to the addition of NADPH to start the reaction. Each value represents the
mean ± S.E. of three experiments carried out in duplicate.
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Lipid droplets accumulate in CPR-/- hepatocytes
In order to evaluate whether squalene monooxygenase is active in the livers of
CPR-/- mice, primary hepatocytes were isolated from CPR-/- mice and wild-type mice.
The hepatocytes isolated from CPR-/- mice appear bulky under the microscope in
comparison to wild-type hepatocytes. The cells were stained with oil red O which stains
the neutral lipids, including sterols and sterol esters (Figure 4.8). The results of oil red O
staining showed that the hepatocytes from CPR-/- mice contains multiple lipid droplets
covering approximately 30% area of the cells, indicating the extensive accumulation of
sterols and neutral lipids. In contrast, there were virtually no sterols and neutral lipids
observed in wild-type hepatocytes. These results indicate that the capacity of the CPR-/cells to remove the neutral lipids is attenuated.
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Figure 4.8: Primary hepatocytes from A) wild-type and B) hepatic CPR-null mice
were stained with Oil Red O. Hepatocytes were prepared from mice at age of 12-16
wks, incubated overnight, fixed in 10% formalin and stained with Oil Red O following
standard procedures Gill's hematoxylin solution was used for counterstaining the nuclei.
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A) wild-type hepatocytes

B) CPR-/- hepatocytes
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Squalene monooxygenase is active in CPR-/- hepatocytes
To exclude the possibility that the squalene monooxygenase reductase activity
found in CPR-/- microsomes was an artifact of the preparation, hepatocytes were
isolated from CPR-/- mice and 2,3-oxidosqualene formation from
monitored by thin-layer chromatography.

14

C-mevalonate was

To prevent oxidosqualene from being

converted to lanosterol, AMO 1618, a cell-permeable inhibitor of oxidosqualene cyclase,
was added to these incubations.
-/-

accumulates in CPR

As shown in Figure 4.9, 2,3-oxidosqualene

cells (os, lane 1). The addition of terbinafine, an inhibitor of

squalene monooxygenase, decreases the oxidosqualene band while causing squalene
to accumulate (sq, lane 2). In untreated cells, both squalene and 2,3-oxidosqualene
were further metabolized and do not accumulate (lane 3). This offers strong evidence
that squalene monooxygenase is enzymatically active in CPR-null hepatocytes. Similar
results are obtained with wild-type cells (lanes 4-7), although the lack of squalene
accumulation in these cells in the presence of an oxidosqualene cyclase inhibitor (lane
4) suggests that squalene monooxygenase is more active in wild-type than in CPR-/cells. Furthermore, to confirm that these two bands are indeed squalene and
oxidosqualene, zaragozic acid A (squalestatin), an inhibitor of squalene synthase, was
added into the medium to prevent the synthesis of both pre-sterols (lane 6), leading to
the disappearance of both squalene and 2,3-oxidosqualene.
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Figure 4.9:

Squalene monooxygenase is active in CPR-/- hepatocytes.

Oxidosqualene

formation

from

14

C-mevalonate

autoradiography of thin-layer chromatograms.

was

monitored

by

2,3-

electronic

A, lipids were extracted from CPR-/-

hepatocytes incubated in the presence of AMO 1618 (lanes 1) with terbinafine (lane 2)
or untreated cells (lane 3); os, oxidosqualene; sq, squalene. B, lipids were extracted
from wild-type hepatocytes incubated in the presence of AMO 1618 (lanes 4-6) with
terbinafine (lane 5) or squalestatin (lane 6). Lane 7 contains lipids from untreated cells.
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Cholesterol biosynthesis is blocked in CPR-/- hepatocytes
Cholesterol synthesis in hepatocytes isolated from CPR-/- mice and wild-type mice
was monitored by incubating with

14

C-mevalonate in the absence of cholesterol

synthesis inhibitors. Lipids were extracted into chloroform: methanol (2:1) and
cholesterol biosynthesis was monitored by thin-layer chromatography. In Figure wildtype animals.

Addition of cytosol from either CPR-/- or wild-type animals to

CPR-/- microsomes in the presence of NADPH but not NADH restored up to 40% of the
squalene monooxygenase activity seen in wild-type microsomes (Figure 4.2).
Essentially no activity is obtained with CPR-null microsomes in the absence of cytosol
and NADPH, indicating a requirement for cytosol and NADPH-dependence. In addition,
virtually no cytochrome P450 reductase exists in cytosol fraction, as detected by
Western blotting for cytochrome P450 reductase (Figure 4.3), suggesting this
stimulation is not due to residual cytochrome P450 reductase in cytosol fraction. 4.10,
lipids from CPR-/- cells exhibit a prominent band with a mobility characteristic of methylsterols (lane 1, ms). Labeled cholesterol is not evident in these cells, but is prominent in
lipids from wild-type cells (lane 2, chol).

In lipids from wild-type cells treated with

ketoconazole, an inhibitor of lanosterol demethylase, cholesterol labeling decreased
and a band corresponding to lanosterol appeared (lane 3, ms). The methyl-sterol that
-/-

accumulates in CPR cells closely resembles lanosterol in mobility.
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Figure 4.10: Cholesterol biosynthesis is blocked in CPR-/- hepatocytes and an
unknown sterol is accumulated.

Cholesterol formation from

14

C-mevalonate was

monitored by electronic autoradiography of thin-layer chromatograms in the absence of
cholesterol synthesis inhibitors. Lipids were extracted from CPR-/- (lane 1) or wild-type
(lanes 2, 3) hepatocytes. Lane 3 contains lipids from cells incubated with ketoconazole.
ms, Methyl-sterol; chol, cholesterol.
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24-Dihydrolanosterol accumulates in CPR-/- hepatocytes
To identify the methyl-sterol that accumulates in CPR-/- cells, lipids from unlabeled
CPR-/- hepatocytes were fractionated by thin-layer chromatography and the methylsterol region on the plate was isolated and subjected to gas-chromatographic massspectrometric analysis. As shown in Figure 4.11, the gas chromatogram revealed a
principal peak at 27.64 min (panel A) which corresponds to 24-dihydrolanosterol by
mass-spectrometric analysis (panel B).

Analysis of a 24-dihydrolanosterol standard

yielded a similar retention time at 27.71 min and an identical ion pattern (panels C and
D), confirming the identity of this sterol. The peak at 27.30 min in the dihydrolanosterol
standard (E) is lanosterol, as determined by mass spectrometric analysis.
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4.11: The unknown sterol is identified as 24-dihydrolanosterol. Lipids from CPR-/hepatocytes were fractionated by thin-layer chromatography and the methyl-sterol
region was eluted and further fractionated by gas chromatography (A). The peak at
27.64 min in panel A was subjected to mass-spectrometric analysis (B), yielding 24dihydrolanosterol

(inset).

Gas

chromatographic

analysis

of

authentic

24-

dihydrolanosterol yielded a peak at 27.71 min (C), which yielded an ion spectral pattern
(D) identical to that in panel B.

The peak at 27.30 min in the 24-hydrolanosterol

standard (C) is lanosterol, as determined by mass-spectrometric analysis (E).

E
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24-Dihydrolanosterol accumulates of in CPR-null livers
Neutral lipids from the wild-type and CPR-/- livers were extracted and analyzed by
GC/MS to determine the levels of cholesterol and of the following cholesterol
precursors: squalene, lanosterol, and 24-dihydrolanosterol.
As shown in Figure 4.12, a total ion chromatogram shows that cholesterol is the
predominant component in both cells types (panel A, E), indicating that the CPR-/hepatocytes were able to maintain cholesterol level by uptake from blood circulation
even though the synthesis of cholesterol was abolished. In addition, attenuation of the
synthesis of bile acids in CPR-/- hepatocytes might contribute to the homeostasis of
cholesterol. Despite the same level of cholesterol in CPR-/- and wild-type livers, Gu et al
found a significant decrease in bile acid synthesis in CPR-null mice (Gu, Weng et al.
2003), indicating that the P450s (CYP7A1, CYP8B1 and CYP27A1) involved in bile acid
synthesis are inactivated as their obligatory electron donor, cytochrome P450
reductase, has been deleted in the hepatocytes.
Comparing panel C to panel G, markedly elevated levels of 24-dihydrolanosterol
were found in CPR-null livers, but this sterol metabolite was not above the background
level in lipids from wild-type mice. Lanosterol was not above the background level in
lipids from both wild-type and CPR-null livers with ion chromatogram of m/z 393 and
retention time at 27.30 min as an indicator for this molecule. In addition, GC/MS also
failed to pick up squalene above the background level in lipids from both wild-type and
CPR-null livers when comparing with authentic squalene standard. The results were
confirmed by co-injection with lipids from wild-type and CPR-null livers.
In summary, the analysis of lipids from the livers of CPR-/- and WT animals
demonstrated an abundance of 24-dihydrolanosterol in CPR-/- livers but not in the lipids
from WT mice. Lanosterol was not prominent in hepatocyte lipids from wild-type and
CPR

-/-

mice, suggesting that this sterol intermediate is readily converted to

dihydrolanosterol from lanosterol by sterol ∆24-reductase (Bae and Paik 1997). The
accumulation of dihydrolanosterol in CPR
-/-

-/-

livers demonstrates that squalene

monooxygenase is active in CPR hepatocytes and indicates that cholesterol synthesis
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is interrupted at lanosterol demethylase, a cytochrome P450 evidently dependent on
CPR.
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Figure 4.12:

Gas chromatographic-mass spectral analysis of sterols isolated

from the livers of CPR-/- and wild-type livers. Sterols from CPR-/- and wild-type mice
livers were extracted and analyzed by gas chromatography-mass spectrometric
analysis. A) Total ion chromatogram of the mixture of sterols from CPR-/- mice liver. B)
The highest peak at 24.71 min has been identified as cholesterol. C) Ion chromatogram
of m/z 395 of sterols from CPR-/- mice liver shows the peak of 24-dihydrolanosterol at
27.63 min. D) The peak at 27.63 min has been identified as 24-dihydrolanosterol. E)
Total ion chromatogram of the mixture of sterols from wild-type mice liver. F) The
highest peak at 24.71 min has been identified as cholesterol. G) Ion chromatogram of
m/z 395 of sterols from wild-type mice liver did not show the peak of 24dihydrolanosterol at 27.63 min above background. H) Gas chromatographic analysis of
authentic squalene yielded a peak at 19.77 min. I) The ion spectral pattern of squalene.
J) Coinjection of sterols from CPR-/- and wild-type mice livers: total ion chromatogram;
K) coinjection of sterols from CPR-/- and wild-type mice livers: ion chromatogram of m/z
395.
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7-Dehydrocholesterol reductase is active in CPR-/- microsomes
The conversion of ergosterol to brassicasterol was used to determine the 7dehydrocholesterol reductase activity in CPR-/- and wild-type microsomes (Honda, Tint
et al. 1996). Figure 4.13 shows a representative GC/MS analysis obtained by incubation
of ergosterol with microsomes while stigmasterol was used as an internal standard.
TMS-ether derivatives of brassicasterol, ergosterol and stigmasterol have the retention
time at 25.42, 26.45 and 27.21 min, respectively. The calibration curve for the weight
ratio of brassicasterol and stigmasterol was established by focusing the ion detector on
m/z 380 for brassicasterol (ion species: brassicasterol-(CH3)2-SiOH) and m/z 484 for
stigmasterol (ion species: stigmasterol+).
As shown in Figure 4.14A, the activity of 7-dehydrocholesterol reductase in CPR-/microsomes is slightly higher than that in wild-type microsomes. Although an antibody
for 7-dehydrocholesterol reductase is not available for Western blotting, it has been
shown the mRNA level of 7-dehydrocholesterol reductase increased by two-fold as
compared to that in wild-type livers (Wang, Chamberlain et al. 2005; Weng, DiRusso et
al. 2005). These results offer strong evidence that 7-dehydrocholesterol reductase is
enzymatically active in CPR-null microsomes. In addition, the activity of 7dehydrocholesterol

reductase

has

phosphorylation/dephosphorylation.

been

reported

to

be

regulated

by

The presence of Mg2+ and ATP significantly

increases the activity of 7-dehydrocholesterol reductase (Shefer, Salen et al. 1998).
When we measured the activity of 7-dehydrocholesterol reductase with and without
ATP, 10-fold lower activity was observed in the absence of ATP in CPR-/- and wild-type
microsomes, which is in agreement with the findings of Shefer et al (Figure 4.14).
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Figure 4.13: A representative gas-chromatogram using ergosterol as substrate for
7-dehydrocholesterol reductase.

Peaks of product (brassicasterol) and ergosterol

catalyzed by 7-dehydrocholesterol, internal standard (stigmasterol) and substrate
(ergosterol) were shown at m/z= 380, 484 and 363, respectively.
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Figure 4.14: Comparison of 7-dehydrocholesterol reductase activity in CPR-/- and
wild-type microsomes. Brassicasterol synthesis was measured in hepatic CPR-null
and wild-type microsomes in dose-dependent pattern with different concentrations of
ergosterol A) in the presence of ATP; B) in the absence of ATP. Each point represents
the mean and standard error of 2 experiments.
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Lipid accumulation in CPR-/- cells alters the expression of cholesterolgenic
enzymes
Despite the block to cholesterol synthesis, lipid droplets accumulate in CPR-/hepatocytes, consistent with the hepatic lipidosis characteristic of these mice (Gu,
Weng et al. 2003; Henderson, Otto et al. 2003). This lipid accumulation apparently
leads to the down-regulation of two key cholesterolgenic enzymes, squalene
monooxygenase (Figure 4.15) and HMG-CoA reductase (Figure 4.16) by half.

In

contrast, the expression of SPF is doubled, consistent with its role in facilitating electron
transfer to squalene monooxygenase by squalene monooxygenase reductase (Figure
4.17). The decrease in HMG-CoA reductase expression contrasts with the modest
increase (~1.5-fold) reported for HMG-CoA reductase mRNA levels in these mice
(Wang, Chamberlain et al. 2005; Weng, DiRusso et al. 2005).

Similarly, although

squalene monooxygenase protein levels were decreased, squalene monooxygenase
mRNA levels were increased 2-fold (Weng, DiRusso et al. 2005) or unchanged (Wang,
Chamberlain et al. 2005).

SPF gene expression was not examined in these two

studies. These results indicate that translational and/or post-translational regulatory
mechanisms are likely operative for these key cholesterolgenic enzymes.
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Figure

4.15:

Quantitative

analysis

of

immunoblot

analysis

of

squalene

monooxygenase. Images were acquired with 2 min exposures of immunoblots
containing twofold serial dilutions of CPR-/- and wild-type microsomes from 20 µg to 2.5
µg total protein. Standard curves were generated with mean band intensity of squalene
monooxygenase from wild-type microsomes and the mean band intensities from CPR-/microsomes were fit into the curve. Images were acquired on a Kodak MM2000 gel
documentation station and analyzed for mean intensity above background.
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Figure 4.16: Quantitative analysis of immunoblot analysis of HMG-CoA reductase.
Images were acquired with 2 min exposures of immunoblots containing twofold serial
dilutions of CPR-/- and wild-type microsomes from 20 µg to 2.5 µg total protein.
Standard curves with mean band intensity of HMG-CoA reductase from wild-type
microsomes were generated and the mean band intensities from CPR-/- microsomes
were fit to the curve. Images were acquired on a Kodak MM2000 gel documentation
station and analyzed for mean intensity above background.
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Figure 4.17: Quantitative analysis of immunoblot analysis of SPF. Images were
acquired with 2 min exposures of immunoblots containing twofold serial dilutions of
CPR-/- and wild-type cytosol from 10 µg to 1.25 µg total protein. Standard curves with
mean band intensity of SPF from wild-type cytosol were generated and the mean band
intensities from CPR-/- cytosol were fit to the curve. Images were acquired on a Kodak
MM2000 gel documentation station and analyzed for mean intensity above background.
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Conclusion and discussion
The selective deletion of hepatic cytochrome P450 reductase results in a marked
decrease in plasma cholesterol levels even while lipids accumulate in the liver (Gu,
Weng et al. 2003; Henderson, Otto et al. 2003, and present data). This contrasting
effect on lipids reflects the essential role of CPR in both the synthesis and degradation
of cholesterol. While it was anticipated that cholesterol synthesis would be interrupted
by the loss of CPR, it was not anticipated that squalene monooxygenase activity would
remain partially intact in these cells. A requirement for CPR in squalene epoxidation
was first suggested by Ono and Bloch (Ono and Bloch 1975) and Ono et al. (Ono,
Ozasa et al. 1977) in studies with partially purified enzymes, and later confirmed by Ono
et al. (Ono, Takahashi et al. 1980) in a reconstituted system with the purified enzymes.
Why was squalene monooxygenase reductase, the enzyme we uncovered here, not
recognized in these early studies? The answer probably lies in the use of Triton X-100
to solubilize the microsomes for fractionation and enzyme purification.

My studies

indicate that Triton X-100 prevents the reduction of squalene monooxygenase by this
second reductase, both in the presence and absence of SPF.

As this nonionic

detergent was included in all assays used to fractionate and purify squalene
monooxygenase, it is not surprising that a detergent-sensitive reductase that also
requires SPF for activity was not discovered. I believe the present studies convincingly
demonstrate the existence of this reductase, but I have no information as to its
properties (other than NADPH-specificity) and do not know of any microsomal redox
proteins that might fulfill this role.
The mechanism by which SPF facilitates this reaction remains unresolved. SPF
was first characterized as a squalene transfer protein (Friedlander, Caras et al. 1980),
but more recent studies are equivocal on this role.

SPF clearly belongs to the

CRAL/TRIO family of lipid binding proteins, which includes Sec14p and α-tocopherol
transfer protein (Stocker, Tomizaki et al. 2002; Porter 2003). However, SPF shows
greatest binding affinity for phosphatidylinositol, whereas squalene is a relatively poor
ligand for this protein (Panagabko, Morley et al. 2003).

The ability of anionic

phospholipids to stimulate squalene monooxygenase (Tai and Bloch 1972) raises the
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possibility that phosphatidylinositol is the physiologic ligand for this cytosolic protein.
Why anionic phospholipids are stimulatory in this system and how SPF and these lipids
interact with squalene monooxygenase and squalene monooxygenase reductase is
unclear; indeed, the stimulation of squalene monooxygenase by SPF may simply reflect
its ability to recruit and/or activate squalene monooxygenase reductase as an additional
electron donor in this pathway.

My studies indicate that SPF does not bind to

nucleotide cofactor affinity resins nor directly catalyze electron transfer to squalene
monooxygenase. Nonetheless, SPF shows some unusual characteristics, including the
ability to be activated by phosphorylation (Singh, Mokashi et al. 2003), to hydrolyze
GTP (Habermehl, Kempna et al. 2005), to suppress tumor cell growth via inhibition of
phosphatidylinositol-3-kinase/Akt signaling (Kempna, Zingg et al. 2003; Ni, Wen et al.
2005), and to stimulate HMG-CoA reductase and cholesterol synthesis when
overexpressed in cultured cells (Mokashi, Singh et al. 2005), the latter of which requires
an interaction with Golgi (Mokashi and Porter 2005).
As demonstrated herein, 24-dihydrolanosterol levels are greatly above background
in the livers of hepatic CPR-/- mice.

The accumulation of this sterol indicates that

lanosterol demethylation, a cytochrome P450-mediated reaction, is blocked, and
lanosterol is serving as a substrate for sterol ∆24-reductase.

Studies with freshly

isolated hepatocytes from CPR-/- mice further demonstrate the de novo synthesis and
accumulation of this methyl-sterol. I thus conclude that, while squalene monooxygenase
is able to obtain electrons from the newly discovered reductase in the absence of CPR,
lanosterol demethylase does not have a significant alternative redox partner. This is in
contrast to yeast, where ergosterol synthesis is minimally maintained in the absence of
CPR by the cytochrome b5 electron transport pathway (Lamb, Kelly et al. 1999). The
alternative electron donor for squalene monooxygenase in yeast has not been
established, but has been assumed to be cytochrome b5. The present studies may
induce a re-examination of this assumption, but it should be noted that a clear ortholog
of SPF does not exist in Saccharomyces.
It has also been suggested that mammalian 7-dehydrocholesterol reductase, the
final step in cholesterol synthesis, is dependent on CPR, based on several indirect
assays (Nishino and Ishibashi 2000). My experiments with this enzyme in reconstituted
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CPR-/- microsomal systems do not support this hypothesis. Surprisingly, the activity of 7dehydrocholesterol reductase was approximately twice as high as in CPR-/- microsomes
as compared to that of wild-type microsomes.

Given that the mRNA level of 7-

dehydrocholesterol reductase increased by two-fold as compared to that in wild-type
livers, I expected that 7-dehydrocholesterol reductase would be as enzymatically active
in CPR-null microsomes as same as in wild-type microsomes. As with squalene
monooxygenase, the activity of 7-dehydrocholesterol reductase is NADPH-dependent,
ruling out a role for cytochrome b5 in these reactions. Unlike squalene monooxygenase,
the activity of 7-dehydrocholesterol reductase in CPR-/- microsomes can be increased
by the addition of ATP to the same extent as in wild-type microsomes, indicating that 7dehydrocholesterol reductase activity is regulated in part by phosphorylation.
Under normal circumstances a block to cholesterol synthesis in CPR-/- hepatocytes
would be expected to up-regulate cholesterol synthesis via the SREBP pathway.
Indeed, a modest increase (~1.5-fold) in HMG-CoA reductase mRNA was reported in
the livers of hepatic CPR-/- animals, with similar increases in the mRNAs for many, but
not all, cholesterolgenic enzymes co-regulated by the SREBP pathway (Wang,
Chamberlain et al. 2005; Weng, DiRusso et al. 2005).

However, this increase is

considerably less than might be expected, likely reflecting the concomitant suppression
of SREBP processing by the inability of the CPR-/- liver to eliminate extra-hepatic
cholesterol as bile acids.

In fact, my studies reveal that HMG-CoA reductase and

squalene monooxygenase protein levels are decreased in the livers of CPR-/- mice,
suggesting that secondary, post-translational mechanisms for the regulation of these
enzymes prevail in CPR-/- hepatocytes.

Interestingly, it has been shown that 4,4’-

dimethylsterols, including lanosterol and 24-dihydrolanosterol, are potent regulators of
HMG-CoA reductase enzyme stability (Song, Javitt et al. 2005).

These cholesterol

precursors, including lanosterol and 24-dihydrolanosterol, promote the formation of a
reductase-Insig complex which is then recognized by a microsomal E3 ligase, gp78,
leading to the ubiquitination and subsequent degradation of HMG-CoA reductase
(Song, Sever et al. 2005). The 50% decrease in HMG-CoA reductase protein levels in
CPR-/- livers found herein suggests that the accumulation of 24-dihydrolanosterol
promotes the degradative of HMG-CoA reductase, but HMG-CoA reductase activity was
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not measured in these experiments, and further studies will be needed to confirm that
these changes in enzyme levels reflect changes in total enzyme activity. Interestingly,
squalene monooxygenase is not known to be subject to post-translational regulation in
this manner, but our finding that protein levels were similarly decreased suggests that
this enzyme may also be regulated by this mechanism, particularly in light of the 2-fold
increase in squalene monooxygenase mRNA levels found by Weng et al. (Weng,
DiRusso et al. 2005).

The 2-fold increase in SPF protein levels suggests an up-

regulation of this protein in response to the loss of CPR, which would facilitate the
reduction of squalene monooxygenase by the squalene monooxygenase reductase
uncovered here.
Cholesterol is an important membrane component as well as a precursor for the
synthesis of the steroid hormones and bile acids. On the other hand, high blood
cholesterol level is a major risk factor for coronary heart diseases. Therefore, the
synthesis and utilization of cholesterol must be tightly regulated in order to prevent
abnormal deposition within the body. Statins, HMG-CoA reductase inhibitors, are the
main treatment for lowering cholesterol. A major side effect of statins includes muscle
weakness. Understanding the unique requirements for electron transfer for different
steps in cholesterol synthesis might lead to new treatment for lowering plasma
cholesterol level with fewer side effects.

Copyright © Li Li 2006
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PART TWO: STUDY OF THE STIMULATORY EFFECT OF CYTOCHROME b5 IN THE
ACTIVATION OF CYP2E1 USING THE HEPATIC CYTOCHROME P450
REDUCTASE-NULL MOUSE MODEL
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CHARTER FIVE: THE STIMULATORY EFFECT OF CYTOCHROME b5 IN THE
ACTIVATION OF CYP2E1
Introduction
Cytochrome b5 is a ubiquitous electron transfer protein capable of accepting and
transferring a single electron with a redox midpoint potential of 20 mV (Porter 2002).
Several b5 isoforms have been isolated, including a membrane-bound endoplasmic
reticular form of b5 which is involved in lipid desaturation; a mitochondria membranebound form of b5 with unknown function; and a cytosolic form whose function is to
reduce hemoglobin in red blood cells. Although the amino acid sequence of the hemebinding domains of the microsomal and mitochondrial cytochromes b5 reveals that only
58% of the amino acids are conserved, they arise from the same gene by different
mRNA splicing, whereas the soluble cytochrome b5 is expressed from a separate gene
(Slaughter, Williams et al. 1982; Lederer, Ghrir et al. 1983; Schafer and Hultquist 1983).
The form of cytochrome b5 associated with the endoplasmic reticulum has been
purified from rat microsomes in the presence of detergents (Carlsen, Christiansen et al.
1988). The 17 kDa protein is composed of two domains: a hydrophobic tail which
anchors the protein to the membrane, and a hydrophilic portion, the heme binding
domain, which is active in redox reactions. The solution-NMR structure of b5 shows that
cytochrome b5 consists of 6 helices and 5 β-strands. The heme is inserted into a
hydrophobic pocket within the catalytic region between four α-helices with a heme edge
exposed to the environment, while the heme iron is coordinated with two completely
conserved histidine side chains, H68 and H44. The ligation of the fifth and sixth
coordination position of the heme iron to histidines prevents its direct interaction with
molecular oxygen (Figure 5.1). However, the protein is able to serve as an electron
transfer intermediate between reductases and oxidative enzymes (Arnesano, Banci et
al. 1999; Schenkman and Jansson 2003).
The endoplasmic reticular-bound cytochrome b5 normally accepts an electron
from NADH-cytochrome b5 reductase and donates the electron to a variety of acceptors
involved in the biosynthesis of desaturated lipids and cholesterol. Alternatively,
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cytochrome b5 can accept an electron from NADPH-cytochrome P450 reductase and
participate in drug metabolism by interacting with some cytochrome P450s (Dailey and
Strittmatter, 1980; Fukushima, Grinstead et al. 1981; Aoyama, Nagatak et al. 1990).
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Figure 5.1: Ribbon structure illustration of solution NMR structure of the B form
of oxidized rat microsomal cytochrome b5 with cofactor heme. The heme iron is
coordinated with histidine side chains of H68 and H44. Protein data bank (1BFX),
viewed with CN3D viewer (Arnesano, Banci et al. 1999).
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Catalytic cycle of cytochrome P450
The catalytic cycle of cytochrome P450s has been studied extensively. The
general P450 reaction scheme is presented in Figure 5.2. The resting form of
cytochrome P450s is a six-coordinated low spin ferric state. The iron-containing heme
of P450 is bound to the enzyme through four porphryin nitrogens and a cysteine, which
gives rise to the characteristic absorbance maximum at 450 nm when reduced and
complexed with CO. A water molecule forms the exchangeable distal ligand trans to the
proximal cysteine. The binding of substrate generates the five-coordinate high spin
ferric state, which results in a significant increase in the redox potential of the heme (330 to -173mV). This allows the electron-donor partner to transfer an electron to the iron
to generate the ferrous iron. Molecular oxygen then becomes bound to the ferrous iron
center to give the ferrous-dioxy complex. Addition of the second electron to the ferrousdioxy complex yields a ferric-peroxide complex leading to the splitting of the oxygenoxygen bond, with the release of one atom as water. The remaining oxygen-iron
complex forms the reactive FeO3+ which is able to oxidize substrate. Uncoupled
turnover of P450s produces superoxide and H2O2 (Guengerich, 2001).
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Figure 5.2: The catalytic cycle of cytochrome P450 enzymes. The iron in brackets
represents the prosthetic heme group of P450s and RH represents a substrate.
Molecular oxygen is split, one atom is utilized to oxidize substrate, and the other atom is
reduced to water (Guengerich, 2001).
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The ability of NADH to stimulate drug metabolism when added to liver microsomes
suggested that the b5 reductase/cytochrome b5 pathway might also contribute to P450mediated reactions (Conney, Brown et al. 1957; Hildebrandt and Estabrook 1971), a
hypothesis supported by studies in which antibodies to cytochrome b5 prevented the
stimulation by NADH (Mannering, Kuwahara et al. 1974; Noshiro, Harada et al. 1979).
The parallel observation that cytochrome P450 reductase was able to transfer electrons
to cytochrome b5 (Enoch and Strittmatter 1979), has complicated efforts to define the
role of the NADH-dependent pathway in P450-mediated metabolism.
An initial study by Hildebrandt and Estabrook (Hildebrandt and Estabrook 1971)
proposed that cytochrome b5 could contribute the second electron to P450 in the
catalytic cycle. However, the recent demonstration by Guengerich and colleagues that
b5 devoid of heme could also stimulate certain P450 reactions called into question the
role of electron transfer in the stimulation by this hemeprotein (Yamazaki, Johnson et al.
1996; Yamazaki, Shimada et al. 2001). Although this has been demonstrated most
clearly for CYP3A4, stimulation by apo- b5 has been now been confirmed for a variety of
P450s, including 2C9, 4A7, and 17 (Porter 2002). In contrast, CYP2E1 differs from
these P450 isoforms in that it appears to require electron transfer from cytochrome b5
for the stimulatory effect (Yamazaki, Gillam et al. 1997; Yamazaki, Nakamura et al.
2002).

Yamazaki et al. (Yamazaki, Nakano et al. 1996) found that a reconstituted

system containing NADH, cytochrome b5 reductase, cytochrome b5, and CYP2E1, but
lacking cytochrome P450 reductase metabolized 7-ethoxycoumarin at about onequarter the rate obtained in the presence of P450 reductase, demonstrating that both
electrons could be derived from the NADH-dependent b5 pathway in vitro. Studies with
microsomes using antibodies to P450 reductase supported this finding (Yamazaki,
Nakano et al. 1996). It has also been reported that CYP 2E1 in a reconstituted system
containing NADH, b5 reductase and cytochrome b5 catalyzes chlorzoxazone 6hydroxylation at about half of the rate obtained with P450 reductase (Yamazaki, Nakano
et al. 1996).
It has been shown that the coexpression of cytochrome b5 with CYP2E1 and P450
reductase

in

heterologous

systems

significantly

enhances

CYP2E1-mediated

metabolism with isolated membrane preparations and in in vivo assays (Patten and
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Koch 1995; Wang, Patten et al. 1996). Moreover, studies with the Ames mutagenicity
assay showed that the NADH-dependent electron transport pathway is fully able to
support CYP2E1 activity in the absence of cytochrome P450 reductase (Cooper and
Porter 2001). In this system all electrons are derived from NADH and must pass through
cytochrome b5 to reach CYP2E1. Omitting either b5 reductase or b5 prevented activity,
as indicated by a lack of nitrosamine-induced revertants in this assay. The presence of
activity with this system clearly demonstrates that cytochrome b5 is capable of providing
both the first and second electron to CYP2E1 in whole cells.
Consistent with the experimental data indicating an interaction between
cytochrome b5 and cytochrome P450 reductase, modeling studies by Gao et al (Gao,
Doneanu et al. 2006) shows that electrostatic interactions are the main stabilizing force
for the interaction of CYP2E1 and cytochrome b5, and contribute to the proper relative
orientations of the prosthetic groups necessary for the electron transfer process. The
negatively charged residues located on the surface region where the b5 heme group
protrudes toward the solvent contribute to electrostatic interactions, along with the
positively charged residues across the the proximal face of CYP2E1 where the buried
CYP2E1 heme group comes closest to the solvent (Gao, Doneanu et al. 2006). The
heme groups of the two proteins were positioned close to each other at a near 90°
angle, supporting the direct electron transfer between these two proteins.
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Experimental rationale
CYP2E1 is a major cytochrome P450 enzyme in liver that catalyzes a variety of
xenobiotic hydroxylations including that of drugs and carcinogens. The stimulatory effect
of cytochrome b5 on CYP2E1 has been thought to result from direct electron transfer of
one or both required electrons to this P450. Transfer of the second electron to
oxyferrous P450 via cytochrome b5 could be from either NADH-cytochrome b5 reductase
or NADPH-cytochrome P450 reductase. However, to date studies have been done only
with purified enzyme systems or by addition of purified b5 into P450 reductase-bearing
microsomes. In the present studies, hepatic cytochrome P450 reductase-null mice, in
which the expression of cytochrome P450 reductase is eliminated during maturation,
were used to evaluate the role of cytochrome b5 in CYP2E1-mediated drug metabolism
using chlorzoxazone as a probe.
Chlorzoxazone is metabolized mainly by CYP2E1 in liver microsomes of various
experimental animals and humans and has been used as a probe drug for CYP2E1mediated metabolism. Although the biotransformation of chlorzoxazone by rat liver
microsomes was fit to a biphasic kinetic profile, suggesting the involvement of multiple
isoforms (Court, Von Moltke et al. 1997), and chlorzoxazone can be metabolized by
CYP 2E1 and CYP1A1 using rat cDNA-expressed CYPs (Warrington, Court et al. 2004),
the majority of kinetic data for liver microsomes from different species, including mouse,
dog and human, followed a one-enzyme Michaelis–Menten model, indicating that
CYP2E1 is the major P450 responsible for the chlorzoxazone biotransformation in these
animals

(Court,

Von

Moltke

et

al.

1997).

6-hydroxychlorzoxazone, is easily detected by HPLC.
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Its

principal

metabolite,

Specific Aims
1) NADH- and NADPH-mediated activities of CYP2E1 were determined using
chlorzoxazone as a probe for CYP2E1 catalytic activity in CPR-/- and wild-type
microsomes. Kinetic analysis was performed, providing an insight into the
mechanism of stimulation by b5.
2) To evaluate whether b5 stimulation is physiologically relevant and takes place in
the CPR-null liver cells, primary hepatocytes from CPR-/- mice and wild-type mice
were isolated and chlorzoxazone metabolism was determined.

Copyright © Li Li 2006
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CHAPTER SIX: MATERIALS AND METHODS
Chemicals
Chlorzoxazone (CLZ), 6OH-chlorzoxazone (6OH-CLZ), phenacetin and other
chemicals and solvents were purchased from Sigma. (St Louis, MO, USA). CLZ, 6OHCLZ, and phenacetin were dissolved in methanol and stored at -20 °C. For incubations,
appropriate volumes of CLZ in methanol were added to the incubation tubes and
evaporated to dryness under reduced pressure in a vacuum oven at room temperature.
Animals
CPR liver-specific knockout mice (Alb-Cre+/–/Cprlox+/+) were generated by crossing
mice expressing liver-specific Cre under control of the an albumin promoter (Alb-Cre)
with two lines of mice bearing a conditional CPR allele (Cprlox+/+) (Gu, Weng et al. 2003;
Wu, Gu et al. 2003). Littermates lacking the Alb-Cre transgene (Alb-Cre–/–/Cprlox+/+) were
designated as wild-type. Two to four month old mice from null and wild-type littermate
groups on mixed C57BL/6 (75%) and 129/Sv (25%) genetic background were used in
the studies. Animals were normally maintained in a temperature-, humidity-, and lightcontrolled facility (70-72°F, 48-52% humidity, 12-hr light/dark cycle) and were allowed
free access to water and food. Animal-use protocols were approved by the Institutional
Animal Care and Use Committee of the respective universities.
Preparation of Microsomes
Animals were killed by CO2 asphyxia, the livers promptly removed, and microsomal
and cytosolic fractions prepared by standard procedures. The microsomal fraction was
resuspended at ~15 mg of protein/ml in 100 mM phosphate buffer, 1mM EDTA, (pH
7.6), aliquoted, and stored at -80 °C. Frozen microsomes were thawed on ice
immediately prior to use. All microsomes used in these studies were frozen and thawed
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once only. Protein content was determined by Coomassie Plus assay reagent kit
(Pierce).
Chlorzoxazone metabolism
In vitro incubations were performed as described with minor modifications (Court,
Von Moltke et al. 1997). Briefly, disposable glass culture tubes containing CLZ (0±1000
mM) were prepared with phosphate buffer (100 mM; pH 7.6), and thawed microsomal
protein (400 ug total protein per tube) was added. The tubes were vortexed and placed
in a 37 °C agitating water bath. Reactions were started by addition of 100 ul of an
NADPH regenerating system (0.5 mM NADP+, 3.75 mM glucose-6-phosphate and 1
unit/mL glucose-6-phosphate dehydrogenase) or 100 ul of an NADH regenerating
system (0.5 mM NAD+, 3.75 mM formic acid and 1 unit/mL formic acid dehydrogenase)
to a final reaction volume of 0.5 ml. After 20 min at 37 °C, the reaction was stopped by
addition of 100 ul 43% H3PO4, vortexed, and immediately cooled on ice. After addition
of 5 mg phenacetin as an internal standard, the mixture was extracted twice with 1 ml of
ethyl acetate. The organic layer was transferred to microcentrifuge tubes and
evaporated under a stream of nitrogen. 120 µl of mobile phase (50 mM KH2PO4 in
water:acetonitrile (75:25 v/v)) was added and vortexed, and the tubes were centrifuged
for 15 min at 16,000 rpm. The supernatant was then transferred to vials for highperformance liquid chromatography (HPLC). The chromatography apparatus (Shimazu,
Japan) consisted of a C18 column (u Bondapack, 300mm X 3.9mm I. D., Waters,
Milford, MA, U.S.A.) with 50 mM KH2PO4 in water:acetonitrile (75:25 v/v) mobile phase
at a flow rate of 1.0 ml/min. Eluants were monitored by ultraviolet absorption at 295 nm
using a variable-wavelength detector. Retention times for 6OH-CLZ, phenacetin, and
CLZ were approximately 7.03, 13.29, and 19.56 min, respectively. Product peak identity
was verified by demonstrating co-elution with the purified 6OH-CLZ standard and
disappearance upon exclusion of cofactors or microsomes from the incubation mixture.
For each run, a calibration curve was prepared using a series of concentrations of pure
6OH-CLZ dissolved in the HPLC mobile phase with the internal standard. Actual
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concentrations of metabolite were calculated by linear regression of the calibration
curve.
Isolation of primary hepatocytes
Hepatocytes were prepared from 12-16-week old mice as follows:

Mice were

anesthetized with urethane and the liver was perfused via the portal vein with 50 ml of
liver perfusion medium (Gibco) followed by 30 ml of liver digestion medium (Gibco).
The liver was removed and transferred into a tissue culture plate and the liver capsule
was removed.

Hepatocytes were dissociated by blunt dissection and twice-filtered

through a double layer of gauze. The cells were pelleted, washed twice, counted, and
viability determined by trypan blue exclusion. Hepatocytes were allowed to attach to
35-mm tissue culture plates (BD Primaria™) in William’s E Medium supplemented with
10% fetal bovine serum, 4 mM L-glutamine, 100 units/ml penicillin, and 100 µg/ml
streptomycin sulfate. After 3 hr the cells were washed by PBS, the medium replaced
with 2ml of Hank´s Balanced Salt Solution (HBSS) and the cells were incubated with
chlorzoxazone for 45min. Cells was scraped from plates and transferred with HBSS
solution into 10 ml of glass tubes and sonicated for 1 min. Chlorzoxazone and its
metabolite were extracted with ethyl acetate as described above.
Gel electrophoresis and immunoblotting
Microsomal proteins were separated by sodium dodecyl sulfate-polyacrylamide gel
electrophoresis on 10% gels ( CYP2E1 and cytochrome P450 reductase) or 15% gels
(cytochrome b5), and then electroblotted to nitrocellulose filters. Immunodetection was
carried out with goat anti-rat CYP2E1, goat anti-rabbit cytochrome P450 reductase, and
goat anti-human b5 as the primary antibody and horseradish peroxidase-conjugated IgG
as the secondary antibody.

Reductase antibody was a gift from Dr. M. J. Coon

(University of Michigan); antibodies to CYP2E1 (Daichi Pure Chemicals) and
cytochrome b5 (Oxford Biomedical Research) were purchased from commercial
suppliers. For immunoquantitation, 25 µg of protein was fractionated by electrophoresis
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and electroblotted to nitrocellulose. The membrane was blocked with 0.05% Tween-20
and 5% defatted milk and then incubated in this same buffer with antibody.

The

immunoblots were developed with a secondary antibody conjugated to horseradish
peroxidase and visualized and quantified by chemiluminescence (Supersignal West
Pico Chemiluminescent Substrate, Pierce) on a Kodak Image Station.
Data analysis
Formation of 6-OH chlorzoxazone was fit to a single-enzyme Michaelis–Menten
model using nonlinear regression: V=VmaxS/(Km+S), where V is the reaction velocity,
S is the substrate concentration, Vmax is the maximum reaction velocity and Km is the
substrate concentration corresponding to 50% Vmax.
Statistical analysis
The points were fit using nonlinear regression with the computer program
GraphPad PRISM (San Diego, CA). The differences between the CPR-/- group and the
wild-type group were compared using a one-way analysis of variance. For both
statistical tests, an alpha value was set at P<0.05.

Copyright © Li Li 2006
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CHAPTER SEVEN: RESULTS AND DISCUSSION
NADH stimulates CYP2E1 activity in wild-type microsomes
Chlorzoxazone was used as a probe for the CYP2E1 activity in CPR-/- and wildtype microsomes. Figure 7.1 shows a representative HPLC analysis obtained by
incubation of chlorzoxazone with wild-type microsomes. Phenacetin was used as an
internal standard. 6-Hydroxychlorzoxazone, phenacetin and chlorzoxazone have the
retention time at 7.03, 13.29 and 19.57 min, respectively. The calibration curve was
generated by the height:height ratio of 6-Hydroxychlorzoxazone:phenacetin.
As shown in Figure 7.2, NADH- and NADPH-dependent formation of 6-OH
chlorzoxazone was evaluated in liver microsomes from CPR-/- mice and wild-type mice.
The reactions were performed in the presence of 3.7 mM NADPH and/or 3.7mM NADH
in the presence of an NADPH regenerating system and/or an NADH regenerating
system, as described under Materials and Methods. With wild-type microsomes,
NADPH served as an effective electron donor for chlorzoxazone 6-hydroxylation.
Addition of NADH along with NADPH doubled the rate of chlorzoxazone hydroxylation;
however, inclusion of only NADH supported only a very low rate of hydroxylation (~5%)
of that obtained with NADPH.
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Figure 7.1: A representative HPLC chromatogram. Peaks of product (6OHchlorzoxazone), internal standard (phenacetin) and substrate (chlorzoxazone) are
shown at 7.03, 13.29 and 19.57 min, respectively.
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Figure 7.2: Effect of NADH and NADPH on hydroxylation of chlorzoxazone in wildtype microsomes. Increasing concentrations of chlorzoxazone were incubated with
pooled liver microsomes from wild type mice (n=6) for 20 min at 37°C in the presence of
NADPH, NADH, or NADPH with NADH. Data was fit to one-site binding model using
Prism. Assays were performed in triplicate and values represent the mean±s.e.
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NADH supports low CYP2E1 activity in CPR-/- microsomes
As shown in Figure 7.3, in microsomes from CPR-/- livers NADH supports
chlorzoxazone metabolism at a rate approximately 20% of that obtained in wild-type
microsomes with NADPH, slightly greater than that seen in wild-type microsomes with
NADH. Thus in both wild-type and CPR-/- microsomes NADH supports a low rate of
CYP2E1 activity. Addition of NADPH to NADH increased the chlorzoxazone
hydroxylation activity in CPR-null microsomes by about one third, but was not
statistically different (P>0.05) from the rate obtained with NADH alone. The use of
NADPH alone did not support chlorzoxazone hydroxylation activity, consistent with the
absence of cytochrome P450 reductase in these microsomes. Maximal catalytic activity
in CPR-/- liver microsomes in the presence of NADPH and NADH is approximately 15%
of the chlorzoxazone hydroxylation observed in wild-type microsomes with the same
cofactors.
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Figure 7.3: Effect of NADH and NADPH on hydroxylation of chlorzoxazone in
CPR-/- microsomes. Increasing concentrations of chlorzoxazone were incubated with
pooled liver microsomes from CPR-/- mice (n=6) for 20 min at 37°C in the presence of
NADPH, NADH, or NADPH with NADH. Data was fit to one-site binding model using
Prism. Assays were carried out in duplicate and values represent the mean±s.e.
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CYP2E1 and cytochrome b5 expression in CPR-/- microsomes
Protein expression of CYP2E1 increased by approximately 4-fold in CPR-/microsomes, as compared to that in wild-type microsomes (Figure 7.4). In addition,
cytochrome b5 expression increased by approximately 40% in CPR-/- microsomes
(Figure 7.5). This may explain the slightly greater chlorzoxazone hydroxylation with
NADH in CPR-/- microsomes, compared to that with NADH in wild-type microsomes.
Expression of cytochrome P450 reductase was undetectable in the CPR-/- microsomes
for these assays (Figure 7.6).
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Figure 7.4: Quatatitive immunoblot analysis of CYP2E1 in CPR-/- and wild-type
microsomes. Images acquired with 2 min exposures of immunoblots containing two
fold serial dilutions of CPR-/- and wild-type microsomes from 20 µg to 2.5 µg total
protein. Standard curves were generated with mean band intensity of CYP2E1 from
wild-type microsomes and the mean band intensities from CPR-/- microsomes were
fitted to the curve. Images were acquired on a Kodak MM2000 gel documentation
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Figure 7.5: Quatatitive immunoblot analysis of cytochrome b5 in CPR-/- and wild
type microsomes. Images acquired with 2 min exposures of immunoblots containing
twofold serial dilutions of CPR-/- and wild-type microsomes from 20 µg to 2.5 µg total
protein. Standard curves were generated with mean band intensity of cytochrome b5
from wild-type microsomes and the mean band intensities from CPR-/- microsomes were
fitted to the curve. Images were acquired on a Kodak MM2000 gel documentation
station and analyzed for mean intensity above background.
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Figure 7.6: Immunoblot analysis of cytochrome P450 reductase in CPR-/- and wildtype microsomes. Images acquired with 2 min exposures of immunoblots containing
two-fold serial dilutions of CPR-/- and wild-type microsomes from 20 µg to 2.5 µg total
protein.
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Kinetic analysis of chlorzoxazone 6-hydroxylation in the CPR-/- and wild-type
microsomes
The effects of NADH and NADPH on the kinetic parameters of chlorzoxazone
hydroxylation in CPR-/- and wild-type microsomes were calculated using a one-enzyme
Michaelis–Menten model using Prism one-site binding model (Figure 7.2 and Figure
7.3). From Table 7.1, with wild-type microsomes, the apparent Km for chlorzoxazone
and Vmax were determined to be 13.01 µM and 1.278 nmol/min/mg protein,
respectively, in the presence of NADPH. Addition of NADH along with NADPH doubles
the apparent Km to 28.16 µM, and increased the apparent Vmax to 2.315 nmol/min/mg
protein. With NADH in wild-type microsomes, apparent Km and Vmax were determined
to be 24.01 µM and 0.1135 nmol/min/mg protein, respectively. In CPR-/- microsomes in
the presence of NADH, the apparent Km, Vmax were 61.07 µM and 0.24 nmol/min/mg
protein. Addition of NADPH along with NADH results in a slight increase in apparent Km
and Vmax, however, there are no statistically significant differences between the two
groups (p>0.05). There is no chlorzoxazone hydroxylation detected with NADPH alone,
consistent with the lack of cytochrome P450 reductase in CPR-/- microsomes.
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Table

1:

Kinetic

analysis

of

NADH-dependent

and

NADPH-dependent

chlorzoxazone 6-hydroxylation in CPR-/- and wild-type microsomes. Data represent
mean ± s.e of duplication determinations. Numbers in parentheses indicate percent of
the activities.

Liver ID

Cofactor(s)
NADH

wild type

Vmax

(µM)

(nmol/min/mg protein)

24.01±4.99

0.1135±0.005 (5%)

NADPH

13.01±2.28

1.278±0.0385 (55%)

NADH+NADPH

28.16±3.61

2.315±0.0627 (100%)

NADH

61.07±18.19

0.245±0.020 (11%)

--

--

33.68±7.93

0.330±0.017 (14%)

NADPH
CPR-/-

Km

NADH+NADPH
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Antibody

to

cytochrome

b5

inhibits

NADH-dependent

chlorozoxazone

hydroxylation
As shown in Figure 7.7, in order to evaluate the role of cytochrome b5 in the
NADH-dependent chlorzoxazone hydroxylation, antibody to cytochrome b5 was
incubated with CPR-/- microsomes prior to assay. Antibody to cytochrome b5 reduced
the CYP2E1-mediated activity in CPR-/- microsomes by approximately 25% at the
highest concentration of antibody tested, indicating the involvement of cytochrome b5 in
the NADH-supported chlorzoxazone hydroxylation. However, antibody to cytochrome b5
failed to fully inhibit this reaction at the highest concentration used, suggesting that
either it is not fully able to prevent the interaction between cytochrome b5 and CYP2E1,
or that the NADH-dependent activity is mediated in part by another unrecognized
electron transfer protein.
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Figure

7.7:

Antibody

to

cytochrome

b5

inhibits

the

NADH-dependent

hydroxylation of chlorzoxazone. 6-Hydroxylation of chlorzoxazone was measured in
CPR-/- liver microsomes in the presence of NADH and polyclonal antibody (0.2 mg/ml)
to b5. Antibody was added to the incubations 30 min prior to the addition of NADH to
start the reaction. Each value represents the mean ± S.E. of two experiments carried
out in duplicate.
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Chlorzoxazone hydroxylation in CPR-/- hepatocytes
Although my studies revealed that NADH could support CYP2E1-mediated
hydroxylation of chlorzoxazone in microsomes from CPR-/- livers, I wanted to determine
if this activity was present in whole cells. Primary hepatocytes are a physiological milieu
that contains normal concentration of enzymes and cofactors, as well as the cellular
regulatory mechanisms to regulate enzymatic reactions. In comparison with many other
in vitro techniques, such as purified enzymes or subcellular fractions, primary
hepatocytes are clearly closer to the in vivo situation in terms of drug metabolism.
Therefore, hepatocytes were isolated from hepatic CPR-/- mice and the synthesis of 6hydrochlozoxazone was measured. The formation of 6-hydroxychlorzoxazone is
negligible in these hepatocytes as compared to that in wild-type hepatocytes; at the
highest concentration, chlorzoxazone hydroxylation activity was less than 1% of wildtype cells, suggesting that the activity found in CPR-/-

microsomes was not

representative of whole cells. However, many factors could contribute to the
discrepancy of drug metabolism using microsomes and hepatocytes. One possibility is
that the abnormal morphology of CPR-/- hepatocytes could make the substrate,
chlorzoxazone inaccessible to the endoplasmic reticulum and therefore inhibit its
metabolism.
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Figure 7.8: Hydroxylation of chlorzoxazone in CPR-/- and wild-type primary
hepatocytes. Hepatocytes were prepared from mice at an age of 12-16 wks. Medium
was replaced by Hank´s Balanced Salt Solution with different concentrations of
chlorzoxazone for 45 min. Samples were performed in duplicate.
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Conclusion and discussion
The cytochrome P450-dependent monooxygenase system is responsible for many
biological processes, including the synthesis of steroid hormones, cholesterol, and the
biotransformation

and

detoxication/activation

of

xenobiotics.

NADH-dependent

stimulation of drug metabolism in liver microsomes suggested that the b5
reductase/cytochrome b5 pathway might also contribute to P450-mediated reactions, as
reviewed by Porter (Porter 2002). Cytochrome b5 has been shown to stimulate
cytochrome P450-mediated drug metabolism with different P450 isoforms and their
substrates. Cytochrome P450 2E1 has been reported to exhibit a reasonable turnover
rate via an NADH–cytochrome b5 pathway (Warrington, Court et al. 2004). Because
most studies that support this postulate have been carried out in vitro with reconstituted
P450 systems, my studies were undertaken to determine what role the NADHcytochrome
-/-

b5

pathway

played

in

CYP2E1-mediated

drug

metabolism

in

-/-

CPR microsomes and in CPR hepatocytes.
My studies have demonstrated CYP2E1 activity in microsomes, but not
hepatocytes, from hepatic CPR-null mice using chlorzoxazone as a probe for CYP2E1
catalytic activity. Microsomes from hepatic CPR-/- mice have NADH-dependent CYP2E1
activity but no NADPH-dependent CYP2E1 activity, suggesting residual cytochrome
P450 reductase is not responsible for chlorzoxazone 6-hydroxylation found in CPR-/microsomes. This NADH-dependent CYP2E1 activity in CPR-/- microsomes contributes
approximately 10% of CYP2E1 activity observed in microsomal preparations with
NADPH from wild-type mice and is approximately twice as high as that seen with NADH
in wild-type microsomes, which can be explained by the increase in the protein
expression of CYP2E1 and cytochrome b5, as my data showed. In hepatic CPR-/- livers,
the expression level of liver cytochrome b5 increased by ~40% and CYP2E1 expression
level increased ~4-fold compared to that in wild-type livers.
The kinetic parameters for the metabolism of chlorzoxazone by microsomes from
CPR-/- and wild-type livers have been determined in my studies. Vmax was greatest
with wild-type microsomes in the presence of NADH+NADPH (2.3 nmol/min/mg
protein). The Vmax obtained with only NADPH was approximately 55% of the rate
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obtained with both cofactors, confirming the stimulatory effect of NADH, and
presumably the cytochrome b5 electron transfer pathway, on CYP2E1 activity.
However, the rate with NADH alone was only about 5% of the rate obtained with both
cofactors, indicating that the NADH-b5 pathway alone was unable to substantially
support CYP2E1 activity.

This finding is consistent with literature reports.

With

CPR-/- microsomes the Vmax obtained in the presence of both cofactors was less than
15% of the combined cofactor rate obtained in wild-type microsomes, and the rate with
NADH alone was only slightly less than the rate obtained in the presence of both
cofactors. This finding suggests that NADPH had very little impact on CYP2E1 activity
in the absence of CPR.

The approximately two-fold greater Vmax for CPR-/-

microsomes with NADH, relative to wild-type microsomes, may reflect the four-fold
higher levels of CYP2E1 and 30% higher levels of cytochrome b5 in CPR-/- microsomes.
Km values for chlorzoxazone did not differ greatly between wild-type and CPR-/microsomes in the presence of either cofactor or combination, and probably do not
reflect significant differences. It would not be expected that the Km for chlorzoxazone
would be affected by the presence or absence of CPR, or by the cofactor included in
these studies.
The reaction mechanism for P450-mediated drug metabolism has been proposed
as a Ping-Pong Bi-Bi mechanism, in which the binding of the second electron is
dependent on the previous binding from electron donor(s) (Masters et al., 1965;
Hiwatachi & Ichikawa, 1979; Mayer & Durrant, 1979; Crankshaw et al., 1979). These
and other early studies show that the rate-limiting step in the P450-mediated
monooxygenase reaction is input of a second electron. The role of cytochrome b5 was
suggested to be to provide the second electron more rapidly from NADH than could be
provided from NADPH via cytochrome P450 reductase (Hilderbrandt and Estabrook,
1971). The inability of the NADH-dependent b5 pathway to drive CYP2E1 activity at
rates seen with NADPH in wild-type preparations

probably stems from the redox

potentials of ferrous cytochrome b5 (+20 mV) (Velick and Strittmatter 1956) and ferric
P450 (approx. -300 mV) (Guengerich 1983): this difference would impede input of the
first electron to P450 and, subsequently, overall turnover. However, as cytochrome b5
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facilitates the second electron transfer, the apparent Vmax increased by 2-fold in the
presence of both cofactors (Figure 7.9).
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Figure 7.9: Redox potential control of the electron flow in microsomal P450dependent system. This figure was adapted from Sevrioukova et al (Sevrioukova, Li et
al, 1999).
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In hepatocytes, my studies suggested that the NADH-cytochrome b5 reductase/ b5
pathway has little ability to catalyze CYP2E1 activity in the absence of cytochrome P450
reductase. Assuming NADH levels are unlikely to be limiting in hepatocytes, the reason
for this inability of the b5 pathway to mediate electron transfer to CYP2E1 in whole cells,
as compared to microsomes, is unclear. These results suggest that cytochrome P450reductase might be absolutely essential for chlorzoxazone metabolism in vivo although
several mechanisms including substrate accessibility to CYP2E1 might be the issue for
the differing results from microsomes and primary hepatocytes. More detailed research
is needed to draw the final conclusion.
Overall, my studies were carried out with CPR-/- microsomes and hepatocytes,
focusing on the cytochrome b5 and CYP2E1 interactions in endoplasmic reticularmembrane electron transport processes with physiological relevance. Future studies
with hepatic CPR-null mice are likely to more clearly elucidate the various roles of
cytochrome b5 in the many monooxygenase reactions that contribute to the therapeutic
and toxicological effects of drugs and xenobiotics.

Copyright © Li Li 2006
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CHAPTER EIGHT: SUMMARY OF RESEARCH
SUMMARY OF RESEARCH
NADPH-cytochrome P450 reductase (CPR) is a flavoprotein containing both FAD
and FMN and functions as the electron donor protein for several oxygenase enzymes
found on the endoplasmic reticulum of eukaryotic cells, including the cytochrome P450s
involved in drug metabolism and sterol biosynthesis. Germ-line deletion of the CPR
gene in mice is lethal during embryogenesis, but it is not clear if this is due to a loss of
cholesterol synthesis or to disruption of other developmental pathways dependent on
this widely-used reductase. In conditional-null mice, in which the CPR gene is deleted
in the liver during maturation, adult animals exhibit an 80% decrease in plasma
cholesterol levels, suggesting a loss in the ability to synthesize cholesterol in the liver.
Squalene monooxygenase is a microsomal enzyme that catalyzes the first
oxidative step in cholesterol biosynthesis, converting squalene to 2,3(s)-oxidosqualene,
the immediate precursor to lanosterol. Unlike other flavoprotein monooxygenases that
obtain electrons directly from NAD(P)H, squalene monooxygenase requires a second
enzyme to provide the electrons necessary for catalysis. For many years it has been
assumed that NADPH-cytochrome P450 reductase, the redox partner for the
microsomal cytochrome P450 monooxygenase system, is this requisite electron donor
protein. My studies with hepatic cytochrome P450-reductase-null mice have revealed a
second microsomal reductase for squalene monooxygenase that was not previously
detected; this second reductase is dependent upon supernatant protein factor, a
cytosolic protein that stimulates squalene monooxygenase, for activity.

Inhibition

studies with antibody to P450 reductase indicate that this second reductase supports up
to 40% of the monooxygenase activity that is obtained with microsomes from normal
mice. Studies carried out with hepatocytes from CPR-null mice demonstrate that this
second reductase is active in whole cells and leads to the accumulation of 24dihydrolanosterol, indicating that lanosterol demethylation, a cytochrome P450mediated reaction, is blocked.

These results suggest that this SPF-dependent
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reductase plays a significant role in supporting squalene monooxygenase but not P450mediated reactions.
7-Dehydrocholesterol reductase, the final enzyme of the cholesterol synthesis,
catalyzes the reduction of the ∆7 double bond of 7-dehydrocholesterol and 7dehydrodesmosterol to yield cholesterol and desmosterol, respectively. It has been
suggested that cytochrome-P450 reductase activity is required for this enzyme activity.
My study shows that 7-dehydrocholesterol reductase is enzymatically active in CPR-null
microsomes with slightly greater activity than that found in wild-type mice, and the
activity is greatly stimulated by the addition of ATP. Thus, CPR is not required for the
activity of 7-dehydrocholesterol reductase.
It has been reported that NADH could provide a synergism for some NADPHsupported drug metabolism, indicating the involvement of cytochrome b5 in cytochrome
P450-mediated monooxygenations. With some substrates, some cytochrome P450s
have shown an obligatory requirement for cytochrome b5. Among them, cytochrome
P450 2E1 has been found to exhibit reasonable rates of turnover via an NADH–
cytochrome b5 pathway in vitro. My studies have revealed CYP2E1 activity with hepatic
CPR-null mice using chlorzoxazone as a probe for CYP2E1 catalytic activity.
Microsomes from hepatic CPR-null mice have shown NADH-dependent CYP2E1
activity and no NADPH-dependent CYP2E1 activity. This NADH-dependent CYP2E1
activity contributes approximately 10% of CYP2E1 activity observed in microsomal
preparations with NADPH from wild-type mice. However, the formation of 6-OHchlorzoxazone is negligible in primary hepatocytes from CPR-/- mice. In these mice, the
expression level of liver cytochrome b5 is only slightly increased, but CYP2E1
expression level increased 3-5 fold compared with that in wild-type mice. These results
indicate that in whole cells there is less effective direct electron transfer of both required
electrons from NADH–cytochrome b5 reductase to P450 than in microsomal preparation
from these animals. Future studies with hepatic CPR-null mice are likely to more clearly
elucidate the various roles of cytochrome b5 in the many monooxygenase reactions that
contribute to the therapeutic and toxicological effects of drugs and xenobiotics.
Copyright © Li Li 2006
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